

**Spring 2020 – Systems Biology of Reproduction**  
**Lecture Outline – Male Reproductive Tract Development & Function**  
**Michael K. Skinner – Biol 475/575**  
**CUE 418, 10:35-11:50 am, Tuesday & Thursday**  
**February 4, 2020**  
**Week 4**

### **Male Reproductive Tract Development & Function**

Embryonic Development and Reproductive Tract Organogenesis

- Overview
- Development of Mullerian Duct vs. Duct Wolffian Duct Derivatives
- Mullerian Inhibiting Substance (MIS)

Male Urogenital Tract Organogenesis

- Prevention of Programmed Cell Death in the Wolffian Duct
- UGS/Prostate/Seminal Vesicle
  1. Prostate Morphogenesis (ductal branching)
  2. Cell-Cell Interactions and Paracrine Factors
  3. Prostate Cancer
- Epididymis/Ductus Deferens
- Role of Androgens (T versus DHT)
  1. Androgen Metabolism
  2. 5  $\alpha$  Reductase Inhibitors
  3. Organ Culture
- Endocrine Disruption

### **Required Reading**

Moses MM and Behringer RR. (2019) *Environ Epigenet.* 25;5(3):dvz017.

Joseph and Vezina (2018) Male Reproductive Tract: Development Overview. in: *Encyclopedia of Reproduction* 2<sup>nd</sup> Ed. Vol. 1, Pages 248-255.

### **References**

Zhao F, Franco HL, Rodriguez KF, Brown PR, Tsai MJ, Tsai SY, Yao HH. Elimination of the male reproductive tract in the female embryo is promoted by COUP-TFII in mice. *Science.* 2017 Aug 18;357(6352):717-720.

Murashima A, Kishigami S, Thomson A, Yamada G. Androgens and mammalian male reproductive tract development. *Biochim Biophys Acta.* 2015 Feb;1849(2):163-70.

- Cunha GR, Sinclair A, Ricke WA, Robboy SJ, Cao M, Baskin LS. Reproductive tract biology: Of mice and men. *Differentiation*. 2019 Nov - Dec;110:49-63.
- Hyuga T, Suzuki K, Acebedo AR, Hashimoto D, Kajimoto M, Miyagawa S, Enmi JI, Yoshioka Y, Yamada G. Regulatory roles of epithelial-mesenchymal interaction (EMI) during early and androgen dependent external genitalia development. *Differentiation*. 2019 Nov - Dec;110:29-35.
- Piprek RP, Damulewicz M, Tassan JP, Kloc M, Kubiak JZ. Transcriptome profiling reveals male- and female-specific gene expression pattern and novel gene candidates for the control of sex determination and gonad development in *Xenopus laevis*. *Dev Genes Evol*. 2019 May;229(2-3):53-72.
- McKey J, Bunce C, Batchvarov IS, Ornitz DM, Capel B. Neural crest-derived neurons invade the ovary but not the testis during mouse gonad development. *Proc Natl Acad Sci U S A*. 2019 Mar 19;116(12):5570-5575.
- Beverly BEJ, Furr JR, Lambright CS, Wilson VS, McIntyre BS, Foster PMD, Travlos G, Earl Gray L Jr. In utero exposure to simvastatin reduces postnatal survival and permanently alters reproductive tract development in the Crl:CD(SD) male rat. *Toxicol Appl Pharmacol*. 2019 Feb 15;365:112-123.
- Croft B, Ohnesorg T, Hewitt J, Bowles J, Quinn A, Tan J, Corbin V, Pelosi E, van den Bergen J, Sreenivasan R, Knarston I, Robevska G, Vu DC, Hutson J, Harley V, Ayers K, Koopman P, Sinclair A. Human sex reversal is caused by duplication or deletion of core enhancers upstream of SOX9. *Nat Commun*. 2018 Dec 14;9(1):5319.
- Bertho S, Herpin A, Branthonne A, Jouanno E, Yano A, Nicol B, Muller T, Pannetier M, Pailhoux E, Miwa M, Yoshizaki G, Schartl M, Guiguen Y. The unusual rainbow trout sex determination gene hijacked the canonical vertebrate gonadal differentiation pathway. *Proc Natl Acad Sci U S A*. 2018 Dec 11;115(50):12781-12786.
- Cunha GR, Baskin L. Development of human male and female urogenital tracts. *Differentiation*. 2018 Sep - Oct;103:1-4.
- Nicol B, Grimm SA, Gruzdev A, Scott GJ, Ray MK, Yao HH. Genome-wide identification of FOXL2 binding and characterization of FOXL2 feminizing action in the fetal gonads. *Hum Mol Genet*. 2018 Dec 15;27(24):4273-4287.
- Gregoire EP, Stevant I, Chassot AA, Martin L, Lachambre S, Mondin M, de Rooij DG, Nef S, Chaboissier MC. NRG1 signalling regulates the establishment of Sertoli cell stock in the mouse testis. *Mol Cell Endocrinol*. 2018 Dec 15;478:17-31.
- Dobbs R, Choe S, Kalmanek E, Harrington DA, Stupp SI, McVary KT, Podlasek CA. Peptide amphiphile delivery of sonic hedgehog protein promotes neurite formation in penile projecting neurons. *Nanomedicine*. 2018 Oct;14(7):2087-2094.
- Chen Y, Yu H, Pask AJ, Fujiyama A, Suzuki Y, Sugano S, Shaw G, Renfree MB. Hormone-responsive genes in the SHH and WNT/ $\beta$ -catenin signaling pathways influence urethral closure and phallus growth. *Biol Reprod*. 2018 Oct 1;99(4):806-816.
- Francis JC, Swain A. Prostate Organogenesis. *Cold Spring Harb Perspect Med*. 2018 Jul 2;8(7).
- St-Jean G, Tsoi M, Abedini A, Levasseur A, Rico C, Morin M, et al. Lats1 and Lats2 are required for the maintenance of multipotency in the Müllerian duct mesenchyme. *Development*. 2019 Oct 18;146(20).
- Yan YL, Batzel P, Titus T, Sydes J, Desvignes T, BreMiller R, Draper B, Postlethwait JH. A Hormone That Lost Its Receptor: Anti-Müllerian Hormone (AMH) in Zebrafish Gonad Development and Sex Determination. *Genetics*. 2019 Oct;213(2):529-553.

- Sansone A, Kliesch S, Isidori AM, Schlatt S. AMH and INSL3 in testicular and extragonadal pathophysiology: what do we know? *Andrology*. 2019 Mar;7(2):131-138.
- Mullen RD, Wang Y, Liu B, Moore EL, Behringer RR. Osterix functions downstream of anti-Müllerian hormone signaling to regulate Müllerian duct regression. *Proc Natl Acad Sci U S A*. 2018 Aug 14;115(33):8382-8387.
- Gonthier K, Poluri RTK, Audet-Walsh É. Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer. *J Steroid Biochem Mol Biol*. 2019 Jul;191:105367.
- Zhang D, Zhao S, Li X, Kirk JS, Tang DG. Prostate Luminal Progenitor Cells in Development and Cancer. *Trends Cancer*. 2018 Nov;4(11):769-783.
- Cunha GR, Vezina CM, Isaacson D, Ricke WA, Timms BG, Cao M, Franco O, Baskin LS. Development of the human prostate. *Differentiation*. 2018 Sep - Oct;103:24-45.
- Hiser WM, Sangiorgio V, Bollito E, Esnakula A, Feely M, Falzarano SM. Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives. *Future Oncol*. 2018 Dec;14(29):3073-3083.
- Hejmej A, Bilinska B. The effects of flutamide on cell-cell junctions in the testis, epididymis, and prostate. *Reprod Toxicol*. 2018 Oct;81:1-16.
- Rinaldi JC, Santos SAA, Colombelli KT, Birch L, Prins GS, Justulin LA, Felisbino SL. Maternal protein malnutrition: effects on prostate development and adult disease. *J Dev Orig Health Dis*. 2018 Aug;9(4):361-372.
- Sullivan R, Mieuisset R. The human epididymis: its function in sperm maturation. *Hum Reprod Update*. 2016 Sep;22(5):574-87.
- Wijayarathna R, Hedger MP. Activins, follistatin and immunoregulation in the epididymis. *Andrology*. 2019 Sep;7(5):703-711.
- Nixon B, De Iuliis GN, Hart HM, Zhou W, Mathe A, et al. Proteomic Profiling of Mouse Epididymosomes Reveals their Contributions to Post-testicular Sperm Maturation. *Mol Cell Proteomics*. 2019 Mar 15;18(Suppl 1):S91-S108.
- Browne JA, Leir SH, Eggener SE, Harris A. Region-specific microRNA signatures in the human epididymis. *Asian J Androl*. 2018 Nov-Dec;20(6):539-544.
- Conine CC, Sun F, Song L, Rivera-Pérez JA, Rando OJ. Small RNAs Gained during Epididymal Transit of Sperm Are Essential for Embryonic Development in Mice. *Dev Cell*. 2018 Aug 20;46(4):470-480.e3.
- Sharma U, Sun F, Conine CC, Reichholz B, Kukreja S, Herzog VA, Ameres SL, Rando OJ. Small RNAs Are Trafficked from the Epididymis to Developing Mammalian Sperm. *Dev Cell*. 2018 Aug 20;46(4):481-494.e6.
- Yang R, Browne JA, Eggener SE, Leir SH, Harris A. A novel transcriptional network for the androgen receptor in human epididymis epithelial cells. *Mol Hum Reprod*. 2018 Sep 1;24(9):433-443.
- Jauregui EJ, Mitchell D, Topping T, Hogarth CA, Griswold MD. Retinoic acid receptor signaling is necessary in steroidogenic cells for normal spermatogenesis and epididymal function. *Development*. 2018 Jul 9;145(13).
- Xu B, Turner SD, Hinton BT. Alteration of transporter activities in the epididymides of infertile initial segment-specific Pten knockout mice. *Biol Reprod*. 2018 Sep 1;99(3):536-545.
- Acebedo AR, Suzuki K, Hino S, Alcantara MC, et al. Mesenchymal actomyosin contractility is required for androgen-driven urethral masculinization in mice. *Commun Biol*. 2019 Mar 8;2:95.

- Hejmej A, Bilinska B. The effects of flutamide on cell-cell junctions in the testis, epididymis, and prostate. *Reprod Toxicol*. 2018 Oct;81:1-16.
- Conley JM, Lambright CS, Evans N, Cardon M, Furr J, Wilson VS, Gray LE Jr. Mixed "Antiandrogenic" Chemicals at Low Individual Doses Produce Reproductive Tract Malformations in the Male Rat. *Toxicol Sci*. 2018 Jul 1;164(1):166-178.
- Sidorkiewicz I, Zaręba K, Wołczyński S, Czerniecki J. Endocrine-disrupting chemicals- Mechanisms of action on male reproductive system. *Toxicol Ind Health*. 2017 Jul;33(7):601-609.
- Picut CA, Ziejewski MK, Stanislaus D. Comparative Aspects of Pre- and Postnatal Development of the Male Reproductive System. *Birth Defects Res*. 2018 Feb 15;110(3):190-227.
- Miller WL, Auchus RJ. The "backdoor pathway" of androgen synthesis in human male sexual development. *PLoS Biol*. 2019 Apr 3;17(4):e3000198.
- Silva JPA, Ramos JG, Campos MS, da Silva Lima D, de Azevedo Brito PV, et al. Bisphenol-S promotes endocrine-disrupting effects similar to those promoted by bisphenol-A in the prostate of adult gerbils. *Reprod Toxicol*. 2019 Apr;85:83-92.
- Loreto-Gómez C, Farías P, Moreno-Macías H, Guzmán C, Riojas-Rodríguez H. Prenatal exposure to persistent organic compounds and their association with anogenital distance in infants. *Reprod Biomed Online*. 2018 Dec;37(6):732-740.
- Horan TS, Marre A, Hassold T, Lawson C, Hunt PA. (2017) Germline and reproductive tract effects intensify in male mice with successive generations of estrogenic exposure. *PLoS Genet*. 20;13(7):e1006885.
- Govero J, Esakky P, Scheaffer SM, et al. (2016) Zika virus infection damages the testes in mice. *Nature*. 540(7633):438-442.
- Bohnenpoll T, Wittern AB, Mamo TM, et al. (2017) A SHH-FOXF1-BMP4 signaling axis regulating growth and differentiation of epithelial and mesenchymal tissues in ureter development. *PLoS Genet*. 10;13(8):e1006951.
- Liu L, Suzuki K, Chun E, Murashima A, et al. (2017) Androgen Regulates Dimorphic F-Actin Assemblies in the Genital Organogenesis. *Sex Dev*. 11(4):190-202.
- Monsivais D, Matzuk MM, Pangas SA. (2017) The TGF- $\beta$  Family in the Reproductive Tract. *Cold Spring Harb Perspect Biol*. 2017 Oct 3;9(10)
- Barrett ES, Swan SH. (2015) Stress and Androgen Activity During Fetal Development. *Endocrinology*. 156(10):3435-41.
- Schjenken JE, Robertson SA. (2015) Seminal Fluid Signalling in the Female Reproductive Tract: Implications for Reproductive Success and Offspring Health. *Adv Exp Med Biol*. 868:127-58.
- Murashima A, Xu B, Hinton BT. (2015) Understanding normal and abnormal development of the Wolffian/epididymal duct by using transgenic mice. *Asian J Androl*. 17(5):749-55.
- Keil KP, Vezina CM. (2015) DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate. *Epigenomics*. 7(3):413-25.
- Teerds KJ, Huhtaniemi IT. (2015) Morphological and functional maturation of Leydig cells: from rodent models to primates. *Hum Reprod Update*. 21(3):310-28.
- Grinspon RP, Rey RA. (2014) When hormone defects cannot explain it: malformative disorders of sex development. *Birth Defects Res C Embryo Today*. 102(4):359-73.
- Welsh M, Suzuki H, Yamada G. (2014) The masculinization programming window. *Endocr Dev*. 27:17-27.

- Schjenken JE, Robertson SA. (2014) Seminal fluid and immune adaptation for pregnancy-- comparative biology in mammalian species. *Reprod Domest Anim.* 49 Suppl 3:27-36.
- Mullen RD, Behringer RR. (2014) Molecular genetics of Müllerian duct formation, regression and differentiation. *Sex Dev.* 8(5):281-96.
- Bromfield JJ. (2014) Seminal fluid and reproduction: much more than previously thought. *J. Assist Reprod Genet.* 31(6):627-36.
- Nixon B, et al. (2015) The microRNA signature of mouse spermatozoa is substantially modified during epididymal maturation. *Biol Reprod.* 93(4):91.
- Murashima A, Xu B, Hinton BT. (2015) Understanding normal and abnormal development of the Wolffian/epididymal duct by using transgenic mice. *Asian J Androl.* 17(5):749-55.
- Ayers KL, Cutting AD, Roeszler KN, Sinclair AH, Smith CA. (2015) DMRT1 is required for Müllerian duct formation in the chicken embryo. *Dev Biol.* 15;400(2):224-36.
- Okazawa M, et al (2015) Region-specific regulation of cell proliferation by FGF receptor signaling during the Wolffian duct development. *Dev Biol.* 1;400(1):139-47.
- Mahawong P, et al. (2014) Prenatal diethylstilbestrol induces malformation of the external genitalia of male and female mice and persistent second-generation developmental abnormalities of the external genitalia in two mouse strains. *Differentiation.* 88(2-3):51-69.
- Keil KP, et al. (2014) Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development. *Dev Biol.* 15;396(2):237-45.
- Wikswa JP. (2014) The relevance and potential roles of microphysiological systems in biology and medicine. *Exp Biol Med (Maywood).* 239(9):1061-72.
- Browne JA, et al. (2014) Open chromatin mapping identifies transcriptional networks regulating human epididymis epithelial function. *Mol Hum Reprod.* 20(12):1198-207.
- Robker RL, et al. (2014) Identification of sites of STAT3 action in the female reproductive tract through conditional gene deletion. *PLoS One.* 1;9(7):e101182.
- Lambeth LS, et al. (2015) Anti-Müllerian Hormone Is Required for Chicken Embryonic Urogenital System Growth but Not Sexual Differentiation. *Biol Reprod.* 93(6):138.
- Pfennig F, Standke A, Gutzeit HO. (2015) The role of Amh signaling in teleost fish - Multiple functions not restricted to the gonads. *Gen Comp Endocrinol.* 1;223:87-107.
- Nalbantoğlu Ö, et al (2015) A novel mutation of AMH in three siblings with persistent Mullerian duct syndrome. *J Pediatr Endocrinol Metab.* 1;28(11-12):1379-82.
- Nothnick WB. (2016) Non-coding RNAs in Uterine Development, Function and Disease. *Adv Exp Med Biol.* 886:171-89.
- Aydoğan Ahabab M, Barlas N. (2015) Influence of in utero di-n-hexyl phthalate and dicyclohexyl phthalate on fetal testicular development in rats. *Toxicol Lett.* 4;233(2):125-37.
- Ferguson LR, et al. (2015) Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. *Semin Cancer Biol.*;35 Suppl:S5-S24.
- Peng YC, Joyner AL. (2015) Hedgehog signaling in prostate epithelial-mesenchymal growth regulation. *Dev Biol.* 1;400(1):94-104.
- Murashima A, Kishigami S, Thomson A, Yamada G. (2015) Androgens and mammalian male reproductive tract development. *Biochim Biophys Acta.* 2015 Feb;1849(2):163-70.
- Browne JA, Yang R, Leir SH, Eggener SE, Harris A. (2015) Expression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions. *Mol Hum Reprod.* 2015 Nov 26. pii: gav066. [Epub ahead of print]

- Koch S, Acebron SP, Herbst J, Hatiboglu G, Niehrs C. (2015) Post-transcriptional Wnt Signaling Governs Epididymal Sperm Maturation. *Cell*. 19;163(5):1225-36.
- Jones S, Boisvert A, Francois S, Zhang L, Culty M. (2015) In utero exposure to di-(2-ethylhexyl) phthalate induces testicular effects in neonatal rats that are antagonized by genistein cotreatment. *Biol Reprod.*;93(4):92.
- Chen X, Wang J, Zhu H, Ding J, Peng Y. (2015) Proteomics analysis of *Xenopus laevis* gonad tissue following chronic exposure to atrazine. *Environ Toxicol Chem*. 34(8):1770-7.
- Li X1, Fang EF2, Scheibye-Knudsen M3, et al. (2014) Di-(2-ethylhexyl) phthalate inhibits DNA replication leading to hyperPARylation, SIRT1 attenuation, and mitochondrial dysfunction in the testis. *Sci Rep*. 22;4:6434.
- Hu Y, Wang R, Xiang Z, Qian W, Han X, Li D. (2014) Mixture effects of nonylphenol and di-n-butyl phthalate (monobutyl phthalate) on the tight junctions between Sertoli cells in male rats in vitro and in vivo. *Exp Toxicol Pathol*. 66(9-10):445-54.
- Powers GL, Marker PC. (2013) Recent advances in prostate development and links to prostatic diseases. *Wiley Interdiscip Rev Syst Biol Med*. 5(2):243-56.
- Ferens-Sieczkowska M, Kowalska B, Kratz EM. (2013) Seminal plasma glycoproteins in male infertility and prostate diseases: is there a chance for glyco-biomarkers? *Biomarkers*. 18(1):10-22.
- Mogielnicka-Brzozowska M, Kordan W. (2011) Characteristics of selected seminal plasma proteins and their application in the improvement of the reproductive processes in mammals. *Pol J Vet Sci*. 14(3):489-99.
- Walker CL. (2011) Epigenomic reprogramming of the developing reproductive tract and disease susceptibility in adulthood. *Birth Defects Res A Clin Mol Teratol*. 91(8):666-71.
- Avellar MC, Siu ER, Yasuhara F, Maróstica E, Porto CS. (2010) Muscarinic acetylcholine receptor subtypes in the male reproductive tract: expression and function in rat efferent ductules and epididymis. *J Mol Neurosci*. ;40(1-2):127-34.
- Carletti MZ, Christenson LK. (2009) MicroRNA in the ovary and female reproductive tract. *J Anim Sci*. 2009 Apr;87(14 Suppl):E29-38.
- Jäämaa S, Laiho M. (2012) Maintenance of genomic integrity after DNA double strand breaks in the human prostate and seminal vesicle epithelium: the best and the worst. *Mol Oncol*. 6(5):473-83.
- Drake RR, White KY, Fuller TW, et al. (2009) Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. *J Proteomics*. 20;72(6):907-17.
- O'Rand MG, Widgren EE, Hamil KG, Silva EJ, Richardson RT. (2011) Functional studies of eppin. *Biochem Soc Trans*. 39(5):1447-9.
- Tian X, Pascal G, Fouchécourt S, Pontarotti P, Monget P. (2009) Gene birth, death, and divergence: the different scenarios of reproduction-related gene evolution. *Biol Reprod*. 80(4):616-21.
- Sullivan R, Saez F. (2013) Epididymosomes, prostasomes, and liposomes: their roles in mammalian male reproductive physiology. *Reproduction*. 14;146(1):R21-35.
- Milardi D, Grande G, Vincenzoni F, Castagnola M, Marana R. (2013) Proteomics of human seminal plasma: identification of biomarker candidates for fertility and infertility and the evolution of technology. *Mol Reprod Dev*. 80(5):350-7.
- Cornwall GA, Von Horsten HH, Whelley S. (2011) Cystatin-related epididymal spermatogenic aggregates in the epididymis. *J Androl*. 32(6):679-85.

- Cornwall GA. (2009) New insights into epididymal biology and function. *Hum Reprod Update*. 15(2):213-27.
- Quintas LE, Noël F. (2009) Mechanisms of adaptive supersensitivity in vas deferens. *Auton Neurosci*. 12;146(1-2):38-46.
- Ruan YC, Shum WW, Belleannée C, Da Silva N, Breton S. (2012) ATP secretion in the male reproductive tract: essential role of CFTR. *J Physiol*. 1;590(Pt 17):4209-22.
- Burkitt M, Walker D, Romano DM, Fazeli A. (2012) Using computational modeling to investigate sperm navigation and behavior in the female reproductive tract. *Theriogenology*. 1;77(4):703-16.
- Nigam SK. (2013) Concise review: can the intrinsic power of branching morphogenesis be used for engineering epithelial tissues and organs? *Stem Cells Transl Med*. 2(12):993-1000.
- Ogino S, Lochhead P, Chan AT, et al. (2013) Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. *Mod Pathol*. 26(4):465-84.
- Cortese R, Kwan A, Lalonde E, Bryzgunova O, et al (2012) Epigenetic markers of prostate cancer in plasma circulating DNA. *Hum Mol Genet*.15;21(16):3619-31.
- Hynes PG, Kelly K. (2012) Prostate cancer stem cells: The case for model systems. *J Carcinog*. 2012;11:6.
- Markert EK, Mizuno H, Vazquez A, Levine AJ. (2011) Molecular classification of prostate cancer using curated expression signatures. *Proc Natl Acad Sci U S A*. 108(52):21276-81.
- Carlsson J, Davidsson S, Helenius G, et al. (2011) A miRNA expression signature that separates between normal and malignant prostate tissues. *Cancer Cell Int*. 27;11(1):14.

## REVIEW ARTICLE

# A gene regulatory network for Müllerian duct regression

Malcolm M. Moses  and Richard R. Behringer\*

Department of Genetics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

\*Correspondence address. Department of Genetics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Tel: +713-834-6327; Fax: +713-834-6339; E-mail: rrb@mdanderson.org

Managing Editor: Mike Skinner

## Abstract

Mammalian embryos initially develop progenitor tissues for both male and female reproductive tract organs, known as the Wolffian ducts and the Müllerian ducts, respectively. Ultimately, each individual develops a single set of male or female reproductive tract organs. Therefore, an essential step for sex differentiation is the regression of one duct and growth and differentiation of the other duct. In males, this requires Müllerian duct regression and Wolffian duct growth and differentiation. Müllerian duct regression is induced by the expression of *Amh*, encoding anti-Müllerian hormone, from the fetal testes. Subsequently, receptor-mediated signal transduction in mesenchymal cells surrounding the Müllerian duct epithelium leads to duct elimination. The genes that induce *Amh* transcription and the downstream signaling that results from *Amh* activity form a pathway. However, the molecular details of this pathway are currently unknown. A set of essential genes for AMH pathway function has been identified. More recently, transcriptome analysis of male and female Müllerian duct mesenchyme at an initial stage of regression has identified new genes that may mediate elimination of the Müllerian system. The evidence taken together can be used to generate an initial gene regulatory network describing the *Amh* pathway for Müllerian duct regression. An *Amh* gene regulatory network will be a useful tool to study Müllerian duct regression, sex differentiation, and its relationship to environmental influences.

**Key words:** sex differentiation; anti-Müllerian hormone; transcription

## Introduction

Classic experiments by Alfred Jost in fetal rabbits identified a Müllerian inhibitor associated with the testis that was required for the regression of the Müllerian ducts [1, 2]. The Müllerian inhibitor was subsequently identified as anti-Müllerian hormone (AMH), also known as Müllerian inhibiting substance (MIS) or factor (MIF) [3]. Molecular studies led to the cloning of the genes encoding AMH and its type II receptor (AMHR2) [4–7]. Human

studies have identified mutations in the AMH and AMHR2 genes, leading to a condition known as persistent Müllerian duct syndrome (PMDS), a rare recessive intersex condition [8]. Males with PMDS have a uterus and fallopian tubes and can have testicular descent abnormalities. Mutations in these two genes have been shown to result in PMDS in human, mouse, and dog [9]. In addition, gene knockout studies in mice have led to the identification of *Amh*, *Amhr2*, and other genes required for Müllerian duct regression (Table 1). Together, there is now

Received 22 May 2019; revised 12 August 2019; accepted 13 August 2019

© The Author(s) 2019. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

**Table 1:** genes that participate in AMH GRN for Müllerian duct regression

Gene	Mutation	Phenotype	Reference
<i>Acvr1</i>	Conditional KO	Normal MD regression	Orvis et al. [36]
<i>Amh</i>	Null	PMDS	Behringer [21]; Arango et al. [22]
<i>Amhr2</i>	Null	PMDS	Mishina et al. [30]; Jamin et al. [31]; Arango et al. [17]
<i>Bmpr1a</i>	Conditional KO	PMDS	Jamin et al. [31]; Orvis et al. [36]
<i>Ctnnb1</i> (beta-catenin)	Conditional KO	PMDS	Kobayashi et al. [41]
<i>Gata4</i>	Binding site mutant or deletion	Normal MD regression	Bouchard et al. [26]
<i>Mmp2</i>	Null	Normal MD regression	Roberts et al. [44]
<i>Smad1/5/8</i>	Conditional KO	PMDS	Orvis et al. [36]
<i>Sp7</i> (Osterix)	Null	Delayed MD regression	Mullen et al. [42]
<i>Wif1</i>	Null	Normal MD regression	Park et al. [46]
<i>Wnt7a</i>	Null	PMDS	Parr and McMahon [34]

Conditional KO, Müllerian duct mesenchyme-specific knockout; MD, Müllerian duct; null, full body knockout; PMDS, persistent Müllerian duct syndrome.

sufficient information to describe the first gene regulatory network (GRN) for Müllerian duct regression. This GRN should provide a useful framework to understand the genetic interactions that lead to Müllerian duct regression, sex differentiation, and its relationship to environmental influences.

## Müllerian Ducts Form in Both Male and Female Embryos

During fetal development, the Wolffian and Müllerian ducts form in both males and females. The Müllerian ducts can differentiate into the oviduct, uterus, and a portion of the vaginal canal. The Wolffian ducts can differentiate into vasa deferentia, epididymides, seminal vesicles, and the ejaculatory ducts. The Müllerian duct is a mesoepithelial tissue that requires the Wolffian duct for its development [10, 11]. Müllerian duct formation begins shortly after the Wolffian duct forms, taking place in three phases: initiation, invagination, and elongation [11]. Initiation consists of the specification of mesonephric epithelial cells to become Müllerian duct cells, characterized by *Lhx1* expression, at about E11.75 in mice. During the invagination phase, the *Lhx1*<sup>+</sup> cells form an invagination that makes contact with the Wolffian duct. The Müllerian duct then elongates along the Wolffian duct [12]. During Müllerian duct elongation, cell proliferation is observed throughout the duct with more proliferating cells at the growing tip. The Müllerian duct crosses the Wolffian duct at E12.5 to gain a medial position and subsequently fuses with the urogenital sinus at E13.5 [13]. *Wnt9b* is expressed in the Wolffian duct [14]. *Wnt9b* knockout mice form Wolffian ducts but do not elongate the Müllerian ducts, suggesting a molecular mechanism for the requirement of the Wolffian duct for Müllerian duct development [14]. Shortly after the Müllerian ducts form, sex differentiation proceeds. In females, the Müllerian system continues to develop into the uterus, oviducts and a portion of the vagina. However, in males the Müllerian ducts are actively eliminated.

## Müllerian Duct Regression Occurs in Male Embryos

A major event in male sex differentiation is Müllerian duct regression. Mesenchyme–epithelia interactions mediate this process to ensure that oviducts and a uterus do not develop within the male body [15]. The cells of the Müllerian duct have a mesoepithelial character during regression [11]. Regression begins shortly after the Müllerian duct connects to the urogenital sinus

at E13.5 in the mouse and is completed by birth. Early stages of regression can be observed by tightly condensed mesenchymal cells surrounding the Müllerian duct with intercellular spaces located more radially [16, 17]. Müllerian duct regression is proposed to occur through at least three mechanisms: epithelial cell migration, epithelial to mesenchymal transformation, and apoptosis [18–20]. Apoptosis is initially detected in the rostral region of the Müllerian duct and subsequently in intermediate and caudal regions [18]. Disruptions in the Müllerian duct basement membrane are followed by epithelial cell entrance into the mesenchymal compartment [18]. The regression of the Müllerian duct is proposed to occur in a rostral to caudal manner [15].

## Genes That Regulate Müllerian Duct Regression

### Anti-Müllerian Hormone (*Amh*)

The first gene knockout in the AMH signaling pathway was in the *Amh* locus [21]. Males homozygous for the targeted *Amh* mutation did not regress the Müllerian ducts, resulting in the development of a uterus, oviducts, and vaginal tissue (Fig. 1). These mutant males had correctly descended testes and Wolffian duct derivatives, including seminal vesicles, vasa deferentia, and epididymides. Only ~10% of the mutant males were fertile. However, sperm from the mutant epididymides were competent to fertilize oocytes *in vitro*. These genetic findings demonstrate that *Amh* produced by the fetal testes is essential for Müllerian duct regression.

The *cis*-regulation of *Amh* transcription was studied *in vitro* and *in vivo* [22, 23]. *In vitro* studies identified interactions of the nuclear hormone receptor steroidogenic factor 1 (SF1) also known as Ad4-binding protein (Ad4BP) or NR5A1 with a 20-bp sequence just upstream of the TATAA motif that is required for *Amh* transcription [23]. About 50-bp upstream of the SF1-binding site is a conserved binding site for the high-mobility group transcription factor SOX9 for activation of *Amh* transcription [24]. SF1- and SOX9-binding site mutations were introduced into the endogenous *Amh* locus by gene targeting in embryonic stem (ES) cells [22]. Surprisingly, males homozygous for the SF1-binding site mutation had normal Müllerian duct regression. Molecular studies showed that *Amh* transcript levels in fetal and postnatal testes were 3-fold lower in comparison to wild type. Thus, the SF1-binding site regulates *Amh* transcript levels. In contrast, males homozygous for the SOX9-binding site mutation were a phenocopy of the *Amh*-null male phenotypes, i.e. PMDS. These findings suggest that SF1 regulates *Amh* transcript



**Figure 1:** PDMS in the mouse. Dissected reproductive tract organs from control (top) and *Amhr2* homozygous mutant (bottom) males. In the mutant, the uterine horns (long arrow) and vas deferens (short arrow) parallel each other down to the testes (t) because of a common connective tissue. In this dissection, the connective tissue has been cut to reveal the dual nature of the reproductive tract. Note that because of the physical constraints imposed by the vas deferens, the uterine horns project caudally instead of rostrally. Images from Behringer [21]

levels and SOX9 is essential for the activation of *Amh* transcription.

There are also multiple GATA-binding sites 5' of the *Amh* transcriptional start site [25]. Recently, male mice homozygous for a 2-bp mutation in one of the GATA-binding sites that abolishes GATA binding (termed *GATAmut*) were generated, using CRISPR genome editing [26]. *GATAmut* homozygotes were found to have a 50% reduction in *Amh* transcripts in their testes [26]. In addition, a 40-bp deletion that included the GATA-binding site and an adjacent SF1-binding site resulted in a 90% reduction in testicular *Amh* transcripts. Although there was a dramatic reduction in *Amh* transcripts, both types of adult mutant males did not retain Müllerian duct derivatives. Apparently, there are still sufficient levels of AMH for Müllerian duct regression in these mouse mutants.

### Anti-Müllerian Hormone Receptor 2 (*Amhr2*)

A 21-day-old rat Sertoli cell cDNA, encoding the type II receptor for AMH, *Amhr2*, was first reported by Baarends *et al.* [5]. Their conclusion was based on protein domain structure, indicating a transmembrane serine/threonine kinase receptor and expression localized in the Müllerian duct of male and female fetuses. *Amhr2* transcripts were detected in the mesenchyme adjacent to the Müllerian duct epithelium during embryogenesis, suggesting that the target cell for AMH action is the Müllerian duct

mesenchyme. *Amhr2* is also expressed in the fetal and postnatal gonads, specifically in Sertoli and granulosa cells [5, 22, 27–29].

A targeted mutation in the mouse *Amhr2* gene was generated by gene targeting in ES cells [30]. Approximately 4.4 kb of *Amhr2*, including exons 1–6, was deleted, replacing these sequences with a neomycin resistance gene expression cassette. Homozygous mutant males were normal in size, had correctly descended testes, and differentiated derivatives of the Wolffian ducts. All of the homozygous mutant males also developed a uterus, oviducts, and partial vagina in addition to their male reproductive organ system. This was a phenocopy of *Amh*-null male mice. Some of the homozygous mutant males were fertile. In addition, two other *Amhr2* loss-of-function alleles have been generated, including *Cre* and *lacZ* knock-ins [17, 31]. Both alleles result in a persistence of Müllerian duct derivatives in homozygous mutant males. These findings demonstrate that *Amhr2* is required for Müllerian duct regression.

The transcriptional regulation of *Amhr2* has been explored [32, 33]. *Wt1* encodes a zinc finger transcription factor. A microarray analysis of ~E11.0 *Wt1* wild-type and null urogenital ridges identified *Amhr2* as a candidate gene regulated by *Wt1*. *Wt1* and *Amhr2* were found to be co-expressed in the urogenital ridge. Three *WT1*-binding sites are within 100-bp of the *Amhr2* transcriptional start site. Biochemical and *in vitro* studies showed that these sequences bind *WT1* and act together to regulate *Amhr2* transcription. More studies are required to determine if these sequences are required for *Amhr2* transcription *in vivo* for Müllerian duct regression.

### *Wnt7a* in the Müllerian Duct Epithelium Induces *Amhr2* Expression in Adjacent Mesenchyme

*Wnt7a* was identified as a gene required for Müllerian duct regression [34]. *Wnt7a* is expressed in the Müllerian duct epithelium in both male and female mice from E12.5 to E14.5 [34]. Expression continues in the Müllerian ducts of females as they differentiate into the oviducts and uterus. *Wnt7a*-null males are born with Müllerian duct derivatives [34]. *In-situ* hybridization analysis of the mutant males showed that *Amhr2* expression was detected in testes but absent in the Müllerian duct mesenchyme [34]. This suggests that the essential function of *Wnt7a* in the *Amh* pathway is to activate *Amhr2* transcription in the Müllerian duct mesenchyme [34]. Thus, *Wnt7a* expressed in the Müllerian duct epithelium signals to the adjacent mesenchyme that induces *Amhr2* transcription making the Müllerian ducts competent to respond to AMH for regression [34].

### *Bmpr1a* and *Acvr1* Encode Type I Receptors That Mediate AMH Signaling

The transforming growth factor (TGF)-beta superfamily consists of >30 cytokines [35]. However, only seven type I receptors have been identified. Thus, TGF-beta family members must share type I receptors to mediate their signal transduction. Two TGF-beta type 1 superfamily receptor genes, *Acvr1* and *Bmpr1a*, have been identified as AMH receptors for Müllerian duct regression [36]. *Acvr1*- and *Bmpr1a*-null mice are embryonic lethal before the Müllerian ducts form [37, 38]. Thus, tissue-specific knockouts were generated. When *Bmpr1a* was knocked out in the Müllerian duct mesenchyme of male mice, Müllerian duct retention was observed in ~50% of the mutants [31, 36]. This Müllerian duct retention phenotype was identical to the phenotype observed for *Amh* and *Amhr2* knockout males. All males with a conditional knockout of *Acvr1* in the Müllerian duct

mesenchyme had Müllerian duct regression [36]. However, when both *Acvr1* and *Bmpr1a* were both knocked out in the Müllerian duct mesenchyme, 100% of the male mutants retained the Müllerian ducts, forming the uterus and oviducts [36]. These results suggest that *Acvr1* and *Bmpr1a* act redundantly in the *Amh*-induced Müllerian duct regression pathway.

### ***Smad1*, *Smad5*, and *Smad8* Act Redundantly to Mediate AMH Signaling**

*Smad* activity has been shown to contribute to Müllerian duct regression within the *Amh* pathway. *Smad1*, *Smad5*, and *Smad8* (also known as *Smad9*) are all expressed in the Müllerian duct mesenchyme [39, 40]. A conditional knockout of *Smad1* in the Müllerian duct mesenchyme resulted in proper Müllerian duct regression, as did a conditional *Smad1/Smad8* knockout [36]. Conditional knockouts of *Smad1* or *Smad8* combined with a *Smad5* conditional knockout resulted in partial Müllerian duct retention [36]. This consisted of only part of the Müllerian duct being retained: caudally, rostrally, and/or on one side. The triple conditional knockout of *Smad1/Smad5/Smad8*, however, resulted in fully retained Müllerian duct derivatives [36]. Therefore, the three *Smad* genes function redundantly within the pathway, likely downstream of *Acvr1* and *Bmpr1a*.

### **Beta-Catenin Is Required for MD Regression**

Multiple *Wnt* genes are expressed in the mesonephros, including *Wnt4*, *Wnt5a*, *Wnt7a*, and *Wnt9b* (gudmap.org). To determine if the canonical WNT pathway was required for Müllerian duct regression, a Müllerian duct mesenchyme-specific knockout of  $\beta$ -catenin was performed [41]. Loss of beta-catenin in the Müllerian duct mesenchyme resulted in the persistent Müllerian duct phenotype in all male mutants. Additionally, AMH was found to be expressed in the Sertoli cells of the mutant testes, implying that loss of  $\beta$ -catenin disrupts the pathway downstream of AMH expression [41]. These results suggest that  $\beta$ -catenin functions specifically in the Müllerian duct mesenchyme to mediate Müllerian duct regression downstream of AMH signaling [41].

### **Osterix Is an AMH-Induced Regulator of Müllerian Duct Regression**

A transcriptome analysis of RNA-seq data generated from purified E14.5 male and female Müllerian duct mesenchyme identified Osterix (*Osx*), also known as *Sp7*, as a male-enriched gene [42]. *Osx* was originally identified as a gene required for osteoblast differentiation [43]. *Osx* is expressed in a sexually dimorphic manner in the Müllerian duct mesenchyme. At E14.5, *Osx* expression is detected in the Müllerian ducts of male fetuses, whereas no expression was detected in the Müllerian ducts of female fetuses [42]. This male-specific expression continues throughout the remaining regression process [42]. In addition, *Osx* expression is lost in male mice lacking *Amhr2* [42]. In contrast, overexpression of human AMH in females, using an MT-hAMH transgene stimulates *Osx* transcription [42]. This *Amh*- and *Amhr2*-dependent, sex-specific expression implies a role for *Osx* in the *Amh* signaling pathway. Additionally, loss of  $\beta$ -catenin expression leads to a reduction in *Osx* transcripts, implying that *Osx* is downstream of  $\beta$ -catenin in the regression pathway [42]. *Osx* knockout males have a 24-h delay in Müllerian duct regression [42]. When compared to wild-type males, *Osx* knockout males showed longer and thicker segments of the Müllerian duct at E15.5, E16.5, and E17.5 but complete regression by E18.5

[42]. Taken together, the data suggest that *Osx* is an AMH-induced gene that contributes to Müllerian duct regression.


### **Other Genes That May Be Involved in Müllerian Duct Regression**

*Mmp2* (matrix metalloproteinase 2) transcripts are detected in the male Müllerian duct mesenchyme [44]. *Mmp2* expression in the Müllerian duct mesenchyme is lost in *Amh*<sup>-/-</sup> male mouse fetuses at E13 and E14 [44]. Pharmacological inhibition of *Mmp2* *in vitro* blocks Müllerian duct regression in male urogenital organ culture [44]. Knockdown of *Mmp2* using morpholino oligonucleotides also resulted in Müllerian duct regression defects in male urogenital organ culture. In contrast, activation of MMPs resulted in Müllerian duct regression in female urogenital organ culture. However, male *Mmp2* mutant mice have normal Müllerian duct regression [44], suggesting that *Mmp2* is not essential for Müllerian duct regression *in vivo* or may act redundantly perhaps with other *Mmp* genes.

*Wif1* (WNT inhibitory factor 1) is a secreted frizzled-related protein that inhibits WNT signaling by binding WNT, blocking binding to receptors [45]. *Wif1* expression is detected in the male Müllerian duct but not the female at E13.5 and E14.5 [46]. *Wif1* transcripts are not detected in *Amhr2*<sup>-/-</sup> male fetuses at E13.5 [46]. Exogenous AMH can induce *Wif1* expression in the Müllerian duct mesenchyme in female urogenital organ culture. Knockdown of *Wif1* expression by siRNA *in vitro* inhibits Müllerian duct regression [46]. However, newborn and 4-week-old *Wif1* knockout male mice did not have residual Müllerian tissues, suggesting that *Wif1* is not essential for Müllerian duct regression *in vivo* or there is gene redundancy.

### **GRNs Describe Pathways That Regulate Biological Processes**

GRNs can be described as control systems, at the genetic level, for living creatures. They can include, but are not limited to, DNA sequence-specific transcription factors and downstream genes. The network consists of the processes by which gene products and sequences function collectively to fulfill a biological task. The gene sequences in this case are targets of transcription factors, including enhancers, insulators, and silencers [47]. GRNs are particularly paramount in development. GRNs, for example, specify morphological structures in organisms by dictating the timing and development of cells and tissues that make up a structure [48]. GRNs, therefore, can be uncovered and visualized to illuminate the proper development and function of an organism. When mapped, a GRN can display nodes, feedback loops, enhancement, inhibition, and much more to represent genetic regulation. Regulatory information placed into GRNs is first uncovered and supported through experimentation. Nodes are often defined from knockout or knockdown experiments, which show that a gene is required for function of the network. Further experimentation then specifies genes that encode regulators of those required genes or regulatory sequences within the genome. Once a GRN has begun to be mapped, it can be used to generate hypotheses for the GRN or biological process affected by the GRN. A GRN from one species can be compared to other GRNs across species for evolutionary study, as GRNs hold the modifications that differentiate one species from another [48]. Medically, GRNs dictate normal bodily function and are, therefore, effective aids in finding causes and solutions for disease. Considering sexual development particularly, GRNs provide information needed to understand how



**Figure 2:** a GRN for AMH-induced Müllerian duct regression. The GRN is divided into domains, representing specific fetal cell types. The interactions contained within a domain occur within that cell type. Each gene in the GRN is depicted as a short horizontal line from which extends a bent arrow indicating transcription. The name of each gene is below the horizontal line. Arrows extending from the transcription arrow of one gene to the horizontal line of another gene indicate transcription factor binding to cis-regulatory elements to enhance transcription. Double arrows between cell-type domains indicate intercellular signaling of a protein. Circles in the GRN indicate intracellular protein activity. White circles indicate multiprotein complexes. Black circles indicate phosphorylation of a protein. Arrows formed by dotted lines indicate interactions that have been observed *in vitro* but not yet confirmed *in vivo*. Boxes containing question marks indicate a predicted site of regulation that has not yet been determined

organisms become sexually differentiated. In the case of this review, we will define our GRN using the studies by Eric Davidson as a guide [49].

### A GRN for Müllerian Duct Regression

Based on the genetic and molecular evidence presented above, we present the first GRN for AMH-induced Müllerian duct regression (Fig. 2). Sertoli cells of the fetal testes express *Sf1/Nr5a1*, *Gata4*, and *Sox9*, encoding transcription factors that directly bind the 5' region of the *Amh* locus. These are among the very few direct interactions between transcription factors and cis-regulatory elements for genes in the GRN. Müllerian duct epithelial cells express and secrete WNT7A that interacts with the adjacent mesenchyme cells to induce the expression of *Amhr2*, making the mesenchyme competent to respond to AMH. AMH secreted by fetal Sertoli cells interacts with AMHR2/BMPR1A/

ACVR1, resulting in phosphorylation of SMAD1/5/8. The transcriptional targets of these SMADs are currently unknown. The requirement of beta-catenin in mesenchyme for Müllerian duct regression suggests that canonical WNT signaling may be required. Beta-catenin regulates *Osx* transcript levels but there are other inputs for *Osx* transcription. Transcriptome comparisons between male and female Müllerian duct mesenchyme have identified numerous genes that are upregulated in males relative to females [42, 46]. These provide candidate genes to be investigated for their roles in Müllerian duct regression. The GRN indicates that environmental influences that alter *Amh* transcriptional regulators (SOX9, NR5A1, and GATA4) could alter Müllerian duct regression. However, more studies are required to investigate how environmental factors might alter transcriptional outputs within the Müllerian duct mesenchyme. In conclusion, this *Amh*-regulated GRN provides a tool to investigate Müllerian duct regression, male sex differentiation, and how it may relate to environmental influences.

### Acknowledgements

We thank Rachel Mullen for helpful comments on the manuscript. R.R.B. was supported by National Institutes of Health (HD30284) and Ben F. Love Endowment.

*Conflict of interest statement.* None declared.

### References

- Jost A. Recherches sur la differentiation sexuelle de l'embryon de lapin. *Arch Anat Microsci Morphol Exp* 1947;36: 271-315.
- Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones. *Recent Prog Horm Res* 1953;8:379-413.
- Josso N, Cate RL, Picard JY, Vigier B, di Clemente N, Wilson C, Imbeaud S, Pepinsky RB, Guerrier D, Boussin L. Anti-Müllerian hormone: the Jost factor. *Recent Prog Horm Res* 1993; 48:1-59.
- Imbeaud S, Faure E, Lamarre I, Mattei MG, di Clemente N, Tizard R, Carre-Eusebe D, Belville C, Tragethon L, Tonkin C, Nelson J, McAuliffe M, Bidart JM, Lababidi A, Josso N, Cate RL, Picard JY. Insensitivity to anti-Müllerian hormone due to a mutation in the human anti-Müllerian hormone receptor. *Nat Genet* 1995;11:382-8.
- Baarends WM, van Helmond MJ, Post M, van der Schoot PJ, Hoogerbrugge JW, de Winter JP, Uilenbroek JT, Karels B, Wilming LG, Meijers JH, et al. A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Müllerian duct. *Development* 1994;120: 189-97.
- Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, Ninfa EG, Frey AZ, Gash DJ, Chow EP, Fisher RA, Bertonis JM, Torres G, Wallner BP, Ramachandran KI, Ragin RC, Manganaro TF, MacLaughlin DT, Donahoe PK. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. *Cell* 1986;45:685-98.
- Picard JY, Benarous R, Guerrier D, Josso N, Kahn A. Cloning and expression of cDNA for anti-Müllerian hormone. *Proc Natl Acad Sci USA* 1986;83:5464-8.
- Picard JY, Cate RL, Racine C, Josso N. The persistent Müllerian duct syndrome: an update based upon a personal experience of 157 cases. *Sex Dev* 2017;11:109-25.

9. Mullen RD, Ontiveros AE, Moses MM, Behringer RR. AMH and AMHR2 mutations: a spectrum of reproductive phenotypes across vertebrate species. *Dev Biol* 2019. doi: 10.1016/j.ydbio.2019.07.006.
10. Kobayashi A, Behringer RR. Developmental genetics of the female reproductive tract in mammals. *Nat Rev Genet* 2003;4:969–80.
11. Orvis GD, Behringer RR. Cellular mechanisms of Müllerian duct formation in the mouse. *Dev Biol* 2007;306:493–504.
12. Huang CC, Orvis GD, Kwan KM, Behringer RR. Lhx1 is required in Müllerian duct epithelium for uterine development. *Dev Biol* 2014;389:124–36.
13. Masse J, Watrin T, Laurent A, Deschamps S, Guerrier D, Pellerin I. The developing female genital tract: from genetics to epigenetics. *Int J Dev Biol* 2009;53:411–24.
14. Carroll TJ, Park JS, Hayashi S, Majumdar A, McMahon AP. Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. *Dev Cell* 2005;9:283–92.
15. Mullen RD, Behringer RR. Molecular genetics of Müllerian duct formation, regression and differentiation. *Sex Dev* 2014;8:281–96.
16. Dyche WJ. A comparative study of the differentiation and involution of the Müllerian duct and Wolffian duct in the male and female fetal mouse. *J Morphol* 1979;162:175–209.
17. Arango NA, Kobayashi A, Wang Y, Jamin SP, Lee HH, Orvis GD, Behringer RR. A mesenchymal perspective of Müllerian duct differentiation and regression in Amhr2-lacZ mice. *Mol Reprod Dev* 2008;75:1154–62.
18. Allard S, Adin P, Gouedard L, Clemente ND, Josso N, Orgebin-Crist MC, Picard JY, Xavier F. Molecular mechanisms of hormone-mediated Müllerian duct regression: involvement of beta-catenin. *Development* 2000;127:3349–60.
19. Austin HB. DiI analysis of cell migration during Müllerian duct regression. *Dev Biol* 1995;169:29–36.
20. Hutson JM, Fallat ME, Kamagata S, Donahoe PK, Budzik GP. Phosphorylation events during Müllerian duct regression. *Science* 1984;223:586–9.
21. Behringer RR. The in vivo roles of Müllerian-inhibiting substance. *Curr Top Dev Biol* 1994;29:171–87.
22. Arango NA, Lovell-Badge R, Behringer RR. Targeted mutagenesis of the endogenous mouse Mis gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. *Cell* 1999;99:409–19.
23. Shen WH, Moore CC, Ikeda Y, Parker KL, Ingraham HA. Nuclear receptor steroidogenic factor 1 regulates the Müllerian inhibiting substance gene: a link to the sex determination cascade. *Cell* 1994;77:651–61.
24. De Santa Barbara P, Bonneaud N, Boizet B, Desclozeaux M, Moniot B, Sudbeck P, Scherer G, Poulat F, Berta P. Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Müllerian hormone gene. *Mol Cell Biol* 1998;18:6653–65.
25. Lasala C, Carre-Eusebe D, Picard JY, Rey R. Subcellular and molecular mechanisms regulating anti-Müllerian hormone gene expression in mammalian and nonmammalian species. *DNA Cell Biol* 2004;23:572–85.
26. Bouchard MF, Bergeron F, Grenier Delaney J, Harvey LM, Viger RS. In vivo ablation of the conserved GATA-binding motif in the Amh promoter impairs Amh expression in the male mouse. *Endocrinology* 2019;160:817–26.
27. Baarends WM, Hoogerbrugge JW, Post M, Visser JA, De Rooij DG, Parvinen M, Themmen AP, Grootegoed JA. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat. *Endocrinology* 1995;136:5614–22.
28. di Clemente N, Wilson C, Faure E, Boussin L, Carmillo P, Tizard R, Picard JY, Vigier B, Josso N, Cate R. Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. *Mol Endocrinol* 1994;8:1006–20.
29. Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK. Developmental expression of a candidate Müllerian inhibiting substance type II receptor. *Endocrinology* 1996;137:160–5.
30. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL, Behringer RR. Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. *Genes Dev* 1996;10:2577–87.
31. Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR. Requirement of Bmpr1a for Müllerian duct regression during male sexual development. *Nat Genet* 2002;32:408–10.
32. Shimamura R, Fraizer GC, Trapman J, Lau YfC, Saunders GF. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor. *Clin Cancer Res* 1997;3:2571–80.
33. Klattig J, Sierig R, Kruspe D, Makki MS, Englert C. WT1-mediated gene regulation in early urogenital ridge development. *Sex Dev* 2007;1:238–54.
34. Parr BA, McMahon AP. Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a. *Nature* 1998;395:707–10.
35. Heldin CH, Moustakas A. Signaling receptors for TGF-beta family members. *Cold Spring Harb Perspect Biol* 2016;8:a022053.
36. Orvis GD, Jamin SP, Kwan KM, Mishina Y, Kaartinen VM, Huang S, Roberts AB, Umans L, Huylebroeck D, Zwijsen A, Wang D, Martin JF, Behringer RR. Functional redundancy of TGF-beta family type I receptors and receptor-Smads in mediating anti-Müllerian hormone-induced Müllerian duct regression in the mouse. *Biol Reprod* 2008;78:994–1001.
37. Mishina Y, Crombie R, Bradley A, Behringer RR. Multiple roles for activin-like kinase-2 signaling during mouse embryogenesis. *Dev Biol* 1999;213:314–26.
38. Mishina Y, Suzuki A, Ueno N, Behringer RR. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. *Genes Dev* 1995;9:3027–37.
39. Clarke TR, Hoshiya Y, Yi Se, Liu X, Lyons KM, Donahoe PK. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. *Mol Endocrinol* 2001;15:946–59.
40. Visser JA. AMH signaling: from receptor to target gene. *Mol Cell Endocrinol* 2003;211:65–73.
41. Kobayashi A, Stewart CA, Wang Y, Fujioka K, Thomas NC, Jamin SP, Behringer RR. beta-Catenin is essential for Müllerian duct regression during male sexual differentiation. *Development* 2011;138:1967–75.
42. Mullen RD, Wang Y, Liu B, Moore EL, Behringer RR. Osterix functions downstream of anti-Müllerian hormone signaling to regulate Müllerian duct regression. *Proc Natl Acad Sci USA* 2018;115:8382–7.
43. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugge B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. *Cell* 2002;108:17–29.

44. Roberts LM, Visser JA, Ingraham HA. Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development. *Development* 2002;**129**:1487–96.
45. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their activities. *Nature* 1999;**398**:431–6.
46. Park JH, Tanaka Y, Arango NA, Zhang L, Benedict LA, Roh MI, Donahoe PK, Teixeira JM. Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMüllerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression. *Dev Biol* 2014;**386**:227–36.
47. Oliveri P, Davidson EH. Gene regulatory network analysis in sea urchin embryos. *Methods Cell Biol* 2004;**74**:775–94.
48. Hinman VF, Nguyen AT, Cameron RA, Davidson EH. Developmental gene regulatory network architecture across 500 million years of echinoderm evolution. *Proc Natl Acad Sci USA* 2003;**100**:13356–61.
49. Oliveri P, Davidson EH. Gene regulatory network controlling embryonic specification in the sea urchin. *Curr Opin Genet Dev* 2004;**14**:351–60.

# MALE REPRODUCTIVE TRACT

## Male Reproductive Tract: Development Overview

Diya B Joseph and Chad M Vezina, University of Wisconsin-Madison, Madison, WI, United States


© 2018 Elsevier Inc. All rights reserved.

### Introduction

Human male reproductive tract development is described in this chapter. The male reproductive tract consists of organs involved in the storage, maintenance and transportation of male reproductive cells. The major structures of the male reproductive tract originate from the endoderm-derived cloaca and the mesoderm-derived Wolffian duct. Male reproductive tract and urinary system development are closely linked and together their structures comprise the urogenital system. All human developmental ages mentioned in this chapter are counted from the day of fertilization.

### Developmental Origins of the Male Reproductive Tract

Gastrulation gives rise to three germ layers: the endoderm, ectoderm and mesoderm. Male reproductive tract development begins early in gestation and involves cells from all three germ layers (Fig. 1). The cloaca is a transient pouch-like structure at the terminal



**Fig. 1** Germ cell layer of origin of male reproductive tract structures. (A) Cross sectional view of a gastrulated embryo showing the three germ layers: endoderm (white), mesoderm (light gray) and ectoderm (dark gray). (B) Sagittal view of the male reproductive tract in a week 5 embryo during the bi-potential stage. (C) Sagittal view of the male reproductive tract in a week 10 embryo after the onset of sexual differentiation. Structures of the reproductive tract are colored according to germ layer of origin.

portion of the endoderm-derived hindgut in the early embryo. The cloaca (Latin for “sewer”) differentiates into the urogenital sinus, bladder, urethra and prostate in males. Paired epithelial Wolffian ducts derive from the mesoderm and insert into the cloaca. Testicular factors including testosterone masculinize male reproductive structures and drive cellular differentiation within them. The Wolffian duct gives rise to the epididymis, vas deferens, seminal vesicle and ejaculatory duct. In the mature adult, sperm from the testes are transported through the epididymis, vas deferens and ejaculatory duct to the urethra. At the urethra, the seminal vesicle and prostate contribute secretions to the ejaculate that promote sperm health. The urethra is the conduit for deposition of sperm during reproduction (Moore and Persaud, 2003).

### Urogenital Sinus, Urethra, and Prostate

Growth and re-positioning of mesenchymal tissue divides the cloaca into the urogenital sinus ventrally and the anorectal sinus dorsally by week 7 of gestation.

#### Urogenital sinus

The ventral portion of the cloaca gives rise to the urogenital sinus (UGS). The UGS is a transient structure comprised of a simple epithelial tube featuring a balloon-shaped central cavity (Fig. 1). Paired Wolffian ducts insert into the UGS around week 4 of gestation. The UGS is divided into three parts:

- The cranial or upper part of the UGS differentiates into the urinary bladder.
- The middle or pelvic portion develops into the pelvic urethra and prostate.
- The caudal or lower part develops into the phallic urethra.

#### Urethra

The urethra develops from the middle and caudal regions of the UGS. The pelvic urethra extends from the bladder to the body wall. The phallic urethra extends from the body wall to the tip of the external genitalia. Urethral glands (Littre’s glands) and bulbourethral glands (Cowper’s glands) emerge as urethral outgrowths around week 12 of gestation.

Lineage tracing studies following the fate of endodermal cells within the developing urogenital tract show that the entire urethral epithelium derives from endoderm (Seifert et al., 2008). The developing urethra forms a stratified epithelium comprised of basal, intermediate, and superficial layers. Epithelial–mesenchymal interactions are crucial for urethral morphogenesis. Sonic hedgehog (SHH) peptide is secreted from epithelium and activates GLI transcription factors in nearby mesenchyme. GLI transcription factors drive bone morphogenetic protein 4 (BMP4) transcription and mesenchymal differentiation. Molecular mapping studies in the mouse embryo reveal a multilayered pelvic urethral mesenchyme consisting of lamina propria, muscularis mucosa, submucosa, and muscularis propria (Abler et al., 2011). Male urethra morphogenesis is guided by androgens, principally by androgen-induced signals from the male urethral mesenchyme that drive urethral epithelium differentiation and remodeling.

#### Prostate

The prostate is a male accessory sex gland positioned at the base of the bladder and surrounding the pelvic urethra. Prostate secretions contribute to the ejaculate and promote sperm health. Prostate ductal development initiates in utero as solid epithelial buds deriving from UGS epithelium. The epithelial buds elongate, branch, and canalize to form a complex ductal system draining into the urethral lumen. Most studies on early prostate development have been carried out in rodents. The early development program of prostate budding is remarkably conserved between rodents and humans, even though their prostates differ anatomically at sexual maturity.

In the human fetus, prostate development occurs in response to testosterone production by testicular Leydig cells around week 7 of gestation. Testosterone acts on androgen receptor (AR)-expressing UGS mesenchymal cells. AR activation increases the abundance of UGS mesenchymal steroid 5 alpha reductase type 2 (SRD5A2). SRD5A2 converts testosterone to the more potent dihydrotestosterone (DHT). DHT binding to AR amplifies androgen signaling in the UGS mesenchyme, which evokes paracrine signaling mechanisms that instruct UGS epithelium to form prostatic buds. Prostate bud outgrowth begins around week 10 of gestation and continues until week 24.

Studies in mice have shown that prostatic bud number and location are precisely controlled. The Nk-3 transcription factor locus-1 (NKX3-1) is the earliest marker of prostate specified UGS epithelial cells. Although prostatic bud formation cannot occur in the absence testosterone, several other factors including SHH, SOX9, HOXB13, and WNT5A are also required for prostatic bud formation and subsequent prostate ductal development.

Prostate formation is dependent on complex epithelial–mesenchymal interactions. Tissue recombination experiments have shown that androgen signaling deriving from UGS mesenchyme not UGS epithelium directs prostate bud formation. However, epithelial AR is required for prostate epithelial cell differentiation and secretory protein production. UGS mesenchyme is organized into distinct zones, and some zones serve as signaling centers to guide prostate morphogenesis. UGS mesenchymal condensations (mesenchymal pads) lie on the UGS periphery, are characterized by *FGF10* mRNA expression, and guide directional outgrowth of prostatic buds (Thomson and Cunha, 1999). Epigenetic mechanisms including DNA methylation and histone acetylation regulate expression of key genes involved in prostate development. DNA methylation controls E-cadherin (CDH1) and AR abundance,

which in turn control prostate bud elongation and timing of bud formation respectively (Keil et al., 2014a,b). Histone acetylation controls BMP2 expression to regulate prostatic ductal branching (Keil et al., 2015).

In later stages, the prostate undergoes branching, canalization and differentiation to form a pseudo-stratified epithelium consisting of basal cells, secretory luminal cells and rare neuroendocrine cells. The prostate increases in size following an upsurge in testosterone production during puberty. The study of early prostate development is receiving renewed interest as the reawakening of embryonic processes has been implicated in the pathogenesis of prostate cancer and benign prostatic hyperplasia.

### **Rete Testis, Epididymis, Vas Deferens, Seminal Vesicle**

The intermediate mesoderm lies between paraxial and lateral plate mesoderm of the fetus and gives rise to ductal structures of the urogenital system. Crests of intermediate mesoderm called urogenital ridges form near the midline and along the cranio-caudal body axis. Early in week 4 of gestation, a non-functional, transient excretory organ called the pronephros develops within the urogenital ridge at the position of the thorax. The rudimentary tubular structures of the pronephros feed into the pronephric duct, which joins the cloaca at approximately week 4 of gestation. The pronephric duct is formed by mesenchymal to epithelial transition of intermediate mesoderm. The pronephros undergoes degeneration through an apoptotic program. The mesonephros forms caudal to the degenerating pronephros late in week 4 of gestation. The mesonephros contains glomeruli and mesonephric tubules that function as temporary kidneys until week 10 of gestation, when the metanephros permanently assumes kidney function. The mesonephric tubules open into mesonephric ducts (also known as Wolffian ducts) which drain into the cloaca. The mesonephros degenerates in the cranial to caudal direction around week 8, leaving a few residual tubules that will give rise to efferent ductules of the testes (Rao and Burnett, 2013).

The Wolffian ducts are precursors for ductal structures of the male reproductive and urinary tracts. The ureteric bud emerges as a Wolffian duct outgrowth near its insertion into the cloaca (Fig. 1). The ureteric bud undergoes branching and differentiation within a specialized mesenchyme called the metanephric blastema to form the metanephros or permanent kidneys. The ureteric bud is also the precursor for the ureters, which connect the kidneys to the bladder. The caudal portion of the Wolffian duct between the ureteric bud and the insertion site into the UGS is called the common nephric duct. Common nephric duct apoptosis positions the ureters at their final insertion site within the bladder, spatially separating the ureteral and Wolffian duct openings to the lower urinary tract. Ureter separation from the Wolffian duct is completed by week 7 of gestation. Paired box 2 (PAX2) expression marks the intermediate mesoderm early after gastrulation. Lineage tracing studies show that the PAX2 expressing intermediate mesoderm gives rise to Wolffian ducts, the ureteric bud and the metanephric blastema (Bouchard et al., 2002).

During the ambisexual stage, two sets of paired genital ducts are present in male and female embryos. The paramesonephric or Müllerian ducts extend in the cranio-caudal direction and lie lateral to the Wolffian ducts. Müllerian duct formation occurs between week 6 and 7 of gestation. Lineage tracing studies in chick and mouse models demonstrate that Müllerian ducts develop from the coelomic epithelial layer, which derives from lateral plate mesoderm. Although Wolffian ducts lie in close apposition to and stimulate Müllerian duct formation, the Wolffian ducts do not contribute epithelial cells to the Müllerian ducts (Guioli et al., 2007; Orvis and Behringer, 2007).

Sexual differentiation of the male reproductive tract begins around week 7 of gestation. Müllerian inhibiting substance (MIS) produced by Sertoli cells and testosterone produced by the interstitial Leydig cells of the fetal testis act on the reproductive tract to induce male differentiation. MIS is a glycoprotein of the TGF- $\beta$  family of growth factors which causes irreversible regression of the Müllerian ducts in males. Testicular MIS production commences by week 8 of gestation and Müllerian duct regression occurs between weeks 8 and 10. The prostatic utricle near the UGS and the appendix testis near the male gonads are Müllerian duct remnants in males. Female reproductive structures including the uterus, vagina and oviducts form in the absence of MIS. Testosterone-mediated AR activation supports Wolffian duct survival in males. Reproductive tract structures derived from the Wolffian ducts are formed between week 9 and 13 of gestation. Regional expression of homeobox (HOX) genes drives segmental differentiation of the Wolffian duct into the epididymis, vas deferens and seminal vesicle. The Wolffian ducts regress in females due to insufficient testosterone to support cell survival (Rao and Burnett, 2013).

#### **Rete testis**

After the mesonephros undergoes regression, the remaining mesonephric tubules form the efferent ductules. The seminiferous tubules, which contain sperm cells, are connected to the efferent ductules by a maze-like network of interconnecting tubes called the rete testis. The ciliated cells lining the rete testis guide sperm into the efferent ductules.

#### **Epididymis**

The efferent ductules, which receive sperm from the testis, drain into the epididymis. The epididymis is a convoluted series of tubules that derives from the portion of the Wolffian duct adjacent to the testis. The epididymis stores and transports sperm.

#### **Vas deferens**

The medial Wolffian duct segment forms the vas deferens. Androgens drive Wolffian duct differentiation into the vas deferens around week 12 of gestation. Smooth muscle surrounding the vas deferens contracts during ejaculation to propel sperm from the epididymis to the urethra.

### **Seminal vesicle**

The seminal vesicles develop as lateral outgrowths from the caudal Wolffian duct segment. The seminal vesicles form around week 10 of gestation, after the onset of testosterone synthesis by the fetal testis. Seminal vesicles contribute secretions to the ejaculate. The most caudal Wolffian duct portion, positioned between the seminal vesicle and the urethra, is called the ejaculatory duct. Ejaculatory ducts drain the contents of the seminal vesicle and vas deferens into the urethra.

### **External Genitalia**

Internal fertilization requires specialized male and female external reproductive organs. Lateral plate mesoderm, endoderm, and surface ectoderm cells contribute to the external genitalia. The initial phase of external genitalia development is essentially the same in males and females. In the later phase, androgens drive masculinization of the external genitalia in males (Blaschko et al., 2012; Yamada et al., 2003).

#### **Early phase: Formation of ambisexual external genitalia**

The early phase of external genitalia development, which occurs between 4 and 7 weeks of gestation, is essentially the same in males and females. This phase occurs independently of androgen action as it happens before the onset of testicular testosterone production. The cloacal membrane, formed by direct contact of the endoderm and surface ectoderm, is intact at 4 weeks of gestation. Proliferating lateral plate mesenchymal cells form paired lateral swellings above the cloacal membrane. These swellings fuse at the midline to form the genital tubercle. The genital tubercle is a bi-potential structure which is the precursor of the penis in males and clitoris in females. Paired mesenchymal swellings called urogenital folds and labio-scrotal swellings form on either side of the cloacal membrane. After cloacal septation around week 7, the cloacal membrane becomes the urogenital membrane ventrally and the anal membrane dorsally. The cloacal membrane ruptures at two sites to form the urethral orifice and the anal opening. The urogenital membrane is bounded by urogenital folds and lies within a temporary indentation on the ventral genital tubercle surface called the urethral groove. The urethral groove is lined by a solid cord of endodermal cells comprising the urethral plate epithelium. The urethral plate epithelium is the region of the phallic urethra distal to the UGS.

Studies in mice have shown that early patterning of the genital tubercle does not depend on androgens but does require Sonic hedgehog (SHH) signaling. Mice harboring inactivating mutations in the SHH gene fail to form external genitalia. SHH signaling from the urethral plate epithelium coordinates cell movements during external genitalia development (Perriton et al., 2002).

#### **Later phase: Sexual differentiation of the external genitalia**

Male testicular androgens induce genital tubercle differentiation into the penis. In females, the genital tubercle fails to elongate and forms the clitoris in the absence of androgens. Testosterone synthesis begins by week 7 and maximal concentrations in the fetus are achieved between weeks 10 and 15 of gestation. Early signs of sexual differentiation in the external genitalia can be detected by week 9 and complete differentiation is achieved by weeks 12–13.

The steroid hormone dihydrotestosterone (DHT) masculinizes the external genitalia. Testosterone is converted to DHT by the action of steroid metabolizing enzymes like SRD5A2 which are expressed in genital tubercle mesenchymal cells. DHT initiates androgen signaling in androgen receptor expressing mesenchymal cells. Interactions between androgen activated mesenchyme and urethral plate epithelium initiate male external genitalia differentiation.

Androgen exposure elongates the genital tubercle into the penis. Early in sexual differentiation, the proximal phallic urethra is a closed hollow tube but the distal portion comprising the urethral plate epithelium remains a solid mass of cells. The urogenital folds lining the penile ventral surface guide midline fusion of the urethral plate, forming a hollow urethral tube that extends the whole length of the penis. The fusion of urogenital folds occurs in a proximal to distal direction, positioning the urethral orifice at the tip of the penis. Hypospadias, a common birth defect, occur from defective fusion of urogenital folds. Specialized mesenchyme induces the differentiation of the distal urethral into a stratified squamous epithelium. The labio-scrotal swellings fuse in the midline to form the scrotum. The skin covering the developing penis is derived from surface ectoderm. Specialized structures of the penis, the corpus cavernosa and the corpus spongiosum, derive from the proliferation and differentiation of mesoderm derived cells.

The Genitourinary Development Molecular Anatomy Project (GUIDMAP) website provides curated information on reproductive tract anatomy, histology, mRNA and protein expression over developmental time ([www.gudmap.org](http://www.gudmap.org)).

## **Signaling Pathways in Male Reproductive Tract Development**

Studies in rodents have greatly advanced our knowledge of signaling pathways involved in male reproductive tract development. **Table 1** provides a parallel chronology of the major events in male reproductive tract development in human and mouse.

### **Sonic Hedgehog Signaling**

Sonic hedgehog (SHH) peptide is a developmental morphogen secreted by epithelial cells. The secreted SHH peptide relieves the repression of smoothened (SMO) by binding to its inhibitor patched (PTC1). SMO activation initiates transcription of Gli transcription factors which are involved in several developmental and morphogenetic processes. SHH is expressed in

**Table 1** Chronology of male reproductive tract development in human and mouse

Human	Internal reproductive tract	External genitalia	Mouse
Week 3	Gastrulation; cloacal membrane forms		E6-E6.5
Week 4	Nephrogenic cord forms pronephros forms cloaca develops from hindgut mesonephros forms Wolffian duct fuses with cloaca (day 26)	Genital tubercle forms	E8.5 E9 E9.5 E9.5–E11.5 E9.5 E11–E11.5
Week 5	Ureteric bud forms (day 28) Cloacal septation begins Common nephric duct apoptosis		E10.5–E11.5 E10.5 E11–E12
Week 6	Müllerian duct forms	Urogenital and labio-scrotal folds form	E12–E13 E14
Week 7	Cloacal septation complete Ureters join bladder Onset of testosterone synthesis	Cloacal membrane rupture	E13–E13.5 E13–E14 E13–E13.5
Week 8	Müllerian ducts reach UGS <i>Onset of sexual dimorphism</i>		E13.5
Week 9	Müllerian duct degeneration Wolffian duct differentiation		E16.5 E16.5–P1
Week 10	Müllerian duct degeneration complete Seminal vesicle forms Prostate forms Wolffian duct differentiation		E16.5 E16.5–E18.5 E16.5–P1
Week 11	Wolffian duct differentiation		E16.5–P1
Week 12	Wolffian duct differentiation		E16.5–P1
Week 13		Urethral tube closure	E16.5
2nd Trimester		Growth of external genitalia Inguinal descent (week 23)	E15.5–P1 E15.5–E17.5
3rd Trimester		Growth of external genitalia Scrotal descent (weeks 24–34)	E15.5–P1 E17.5–P20

Provides a parallel chronology of male internal reproductive tract and external genitalia development in the human and mouse. Developmental age in humans is depicted here in weeks from the time of fertilization. Developmental age in the mouse embryo is depicted as days (E) from the time of fertilization.

hindgut-derived structures including the cloacal epithelium, where it patterns the surrounding mesenchyme. SHH induces mesenchymal *GLI2*, which regulates epithelial and mesenchymal proliferation and apoptosis during cloacal development. SHH regulates cloacal septation by promoting proliferation of mesenchymal cells in the urorectal septum (Seifert et al., 2009). SHH signaling is required for prostate formation and external genitalia development. Treatment with SHH inhibitors impairs prostate ductal growth and morphogenesis (Podlasek et al., 1999). SHH knockout mice show a complete absence of external genitalia (Haraguchi et al., 2001).

### WNT-Beta Catenin Signaling

WNT ligand binding to cell surface Frizzled receptors stabilizes and activates the transcription factor beta-catenin. WNT signaling is involved in several aspects of urogenital development including the septation of the cloaca into the urogenital and anorectal sinuses. Disruption of WNT signaling results in rectourethral fistulas (abnormal connection between the urethra and rectum). Epithelial beta-catenin is also required for prostate development and growth (Mehta et al., 2013). The WNT-beta catenin pathway acts downstream of SHH signaling to regulate external genitalia development (Miyagawa et al., 2009).

### Bone Morphogenetic Proteins

Bone morphogenetic proteins (BMPs) are growth factors belonging to the TGF-beta superfamily. BMPs bind to serine threonine kinase receptors and initiate intracellular signaling through SMAD proteins. BMP7 expression in the urorectal septum is required for cloacal septation. In addition, BMP7 expression maintains proliferation and cell survival in the cloacal epithelium (Xu et al., 2012). Expression of BMP7 in the UGS mesenchyme restricts prostate ductal budding and prevents excessive branching of elongating ducts (Grishina et al., 2005).

### Fibroblast Growth Factors

Fibroblast growth factors are a family of secreted growth factors that signal through tyrosine kinase fibroblast growth factor receptors to regulate proliferation, differentiation and morphogenesis during embryonic development. FGF signaling is required for cell survival during the early stages of genital tubercle outgrowth. FGF signaling in the ectoderm is required for urethral tube formation. Deletion of FGF10 or its receptor FGFR2 results in severe hypospadias (Harada et al., 2015). FGFR2, a critical regulator of prostate development, is required for branching and growth of prostate buds. FGF10 is a paracrine mediator of epithelial to mesenchymal signaling during prostate bud formation. FGF10 knockout mice fail to form prostate, seminal vesicle, bulbourethral glands and caudal vas deferens (Thomson and Cunha, 1999).

### PAX Genes

Paired box (PAX) genes are tissue specific transcription factors that determine lineage specification in the early embryo. PAX2 and PAX8 are required for Wolffian duct formation from the intermediate mesoderm. In PAX2 and PAX8 double mutant mice, the intermediate mesoderm fails to undergo the mesenchymal to epithelial transition required for Wolffian duct formation (Bouchard et al., 2002). GATA3, a downstream effector of PAX2, regulates Wolffian duct growth and caudal extension which is required for fusion with the cloaca and formation of definitive kidneys (Grote et al., 2006).

### EPH Receptors/Ephrins

EPH receptors are a family of receptor tyrosine kinases with plasma membrane bound ligands called ephrins. EPH receptor/ephrins are involved in the maintenance of cell-cell adhesion and communication between similar or different cell types during developmental processes. The ephrin receptors EPHA4 and EPHA7 are expressed in the mesenchyme surrounding the cloaca and Wolffian duct where they mediate Wolffian duct fusion with the cloaca (Weiss et al., 2014). Signaling from EPHA4 and EPHB2 is required for apoptosis of the common nephric duct for proper separation of ureters from Wolffian ducts (Peuckert et al., 2016). EphrinB1 expressed by prostatic mesenchyme regulates prostate growth and branching (Ashley et al., 2010).

### Vitamin A/Retinoic Acid Signaling

Retinoic acid, a derivative of vitamin A (retinol), binds to nuclear retinoic acid receptors to activate transcriptional programs for differentiation and organogenesis. The spatial expression of retinaldehyde dehydrogenases, which convert retinaldehyde to retinol, is tightly regulated in a tissue specific manner. Apoptosis induced by retinoic acid signaling is required for ureter separation from the Wolffian duct and proper positioning in the bladder (Batourina et al., 2005). Retinoic acid is a powerful inducer of prostate budding (Vezina et al., 2008a). Retinoic acid signaling regulates external genitalia formation by maintaining SHH and BMP4 expression in the genital tubercle (Liu et al., 2012).

### Müllerian Inhibiting Substance

Müllerian inhibiting substance (MIS) or anti-Müllerian hormone (AMH) is a gonadal hormone secreted by Sertoli cells of the developing testis. The secreted glycoprotein MIS belongs to the TGF-beta family of transcription factors. MIS acts through AMH Type II receptors expressed by Müllerian duct mesenchyme to initiate apoptosis and degeneration of the Müllerian duct (Behringer, 1995; Abler et al., 2011).

### Androgens, INSL3

Testosterone synthesis initiates from fetal Leydig cells during week 7 of gestation. Testosterone is converted to the more potent dihydrotestosterone (DHT) by the enzyme SRD5A2. DHT acts on AR expressing cells to initiate androgen-dependent transcriptional programs. DHT regulates prostate and seminal vesicle formation, external genitalia masculinization and formation of the vas deferens and epididymis. The Leydig cell specific insulin-like peptide INSL3 binds to relaxin/insulin like family peptide receptor 2 (RXFP2) to promote testicular descent into the scrotum (Barsoum and Yao, 2006).

### Endocrine Disruptors

Environmental toxins with the capability of interfering with endocrine signaling are known as endocrine disruptors (Prusinski et al., 2016). In utero exposure to endocrine disruptors adversely affects hormone-dependent development and increases risk of adulthood disease. Maternal exposure to low doses of Bisphenol A, an estrogenic compound found in plastics, has been shown to increase prostate size in rodent models (Gupta, 2000; Dolinoy et al., 2007). Early exposure to Bisphenol A can also increase the risk of prostate cancer in rodent models of estrogen-induced carcinogenesis by inducing long-term changes to the DNA methylome (Cheong et al., 2016). The anti-androgenic endocrine disruptor vinclozolin found in fungicides, can induce

hypospadias in mice (Buckley et al., 2006). In utero exposure to persistent environmental pollutants called 2,3,7,8 tetrachlorodibenzo-*p*-dioxin impairs reproductive function of male and female rodents (Gray and Ostby, 1995; Bjerke and Peterson, 1994). In utero dioxin exposure disrupts mouse prostate formation (Vezina et al., 2008b) and sensitizes mice to hormone-mediated urinary dysfunction (Ricke et al., 2016).

### Congenital Anomalies of the Male Reproductive Tract

Congenital anomalies of the male reproductive tract can reduce fertility. Hypospadias are the most common congenital anomaly of the male reproductive tract, with an occurrence of 1 in 250 live male births. Hypospadias occur when the urethral opening is not at the tip of the penis, but instead on the ventral surface or scrotal region. Defects in urethral tube closure result in hypospadias (Baskin and Ebbers, 2006). Genetic, endocrine and environmental factors have been implicated in the occurrence of hypospadias. Epispadias, which occur when the urethral opening is on the dorsal surface of the penis, is a much rarer condition (affecting 1 in 117,000 males) (Gearhart and Jeffs, 1992). Unlike hypospadias, epispadias result from defects in the cloacal membrane (Suzuki et al., 2017). Another congenital anomaly called chordee is associated with increased curvature of the penis. A congenital condition called posterior urethral valves is associated with the occurrence of flaps of urethral tissue that obstruct urine flow and impair reproductive function (Agarwal, 1999).

Persistent Müllerian duct syndrome is a rare anomaly of the reproductive tract in which Müllerian duct derivatives (uterus and oviduct) persist in males. The persistence of Müllerian duct derivatives can be due to insufficient production of Müllerian inhibiting substance (MIS) or insensitivity of the Müllerian duct to MIS (Elias-Assad et al., 2016).

Congenital anomalies of Wolffian duct derivatives include ectopic insertion of the ureter into the urethra, seminal vesicle, ejaculatory duct or vas deferens. Ectopic ureters are a result of abnormal ureteric bud formation and abnormal separation from the Wolffian duct during kidney development. Ectopic ureter insertion into the seminal vesicle results in the development of congenital seminal vesicle cysts. Seminal vesicle anomalies on their own do not contribute to male infertility. However, these defects are often observed with other Wolffian duct defects that affect fertility (Kroovand and Perlmutter, 1981).

Defects in vas deferens development are a major cause of male infertility. Congenital bilateral absence of the vas deferens results in male infertility from obstructive azoospermia (lack of sperm in semen). This condition is highly prevalent in males who have abnormal mucus production from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Abnormal mucus production in affected individuals results in obstruction and destruction of the vas deferens, leading to infertility in later life (Stuhrmann and Dork, 2000). Other congenital anomalies of Wolffian duct derivatives include agenesis of the epididymis, epididymal cysts with loss of continuity, agenesis of the seminal vesicle and agenesis of the ejaculatory duct.

### References

- Abler, L. L., Keil, K. P., Mehta, V., Joshi, P. S., Schmitz, C. T., & Vezina, C. M. (2011). A high-resolution molecular atlas of the fetal mouse lower urogenital tract. *Developmental Dynamics*, 240, 2364–2377.
- Agarwal, S. (1999). Urethral valves. *BJU International*, 84, 570–578.
- Ashley, G. R., Cathal Grace, O., Vanpoucke, G., & Thomson, A. A. (2010). Identification of Ephrinb 1 expression in prostatic mesenchyme and a role for Ephb–Ephrinb Signalling in prostate development. *Differentiation*, 80, 89–98.
- Barsoum, I., & Yao, H. H. (2006). The road to maleness: From testis to Wolffian duct. *Trends in Endocrinology and Metabolism*, 17, 223–228.
- Baskin, L. S., & Ebbers, M. B. (2006). Hypospadias: Anatomy, etiology, and technique. *Journal of Pediatric Surgery*, 41, 463–472.
- Batourina, E., Tsai, S., Lambert, S., Sprengle, P., Viana, R., Dutta, S., Hensle, T., Wang, F., Niederreither, K., McMahon, A. P., Carroll, T. J., & Mendelsohn, C. L. (2005). Apoptosis induced by vitamin A signaling is crucial for connecting the ureters to the bladder. *Nature Genetics*, 37, 1082–1089.
- Behringer, R. R. (1995). The Mullerian inhibitor and mammalian sexual development. *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences*, 350, 285–288. discussion 289.
- Bjerke, D. L., & Peterson, R. E. (1994). Reproductive toxicity of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin in male rats: Different effects of in utero versus Lactational exposure. *Toxicology and Applied Pharmacology*, 127, 241–249.
- Blaschko, S. D., Cunha, G. R., & Baskin, L. S. (2012). Molecular mechanisms of external genitalia development. *Differentiation*, 84, 261–268.
- Bouchard, M., Souabni, A., Mandler, M., Neubuser, A., & Busslinger, M. (2002). Nephric lineage specification by Pax2 and Pax8. *Genes & Development*, 16, 2958–2970.
- Buckley, J., Willingham, E., Agras, K., & Baskin, L. S. (2006). Embryonic exposure to the fungicide Vinclozolin causes Virilization of females and alteration of progesterone receptor expression in vivo: An experimental study in mice. *Environmental Health*, 5, 4.
- Cheong, A., Zhang, X., Cheung, Y. Y., Tang, W. Y., Chen, J., Ye, S. H., Medvedovic, M., Leung, Y. K., Prins, G. S., & Ho, S. M. (2016). DNA Methylome changes by estradiol benzoate and bisphenol a links early-life environmental exposures to prostate cancer risk. *Epigenetics*, 11, 674–689.
- Dolinoy, D. C., Huang, D., & Jirtle, R. L. (2007). Maternal nutrient supplementation counteracts bisphenol a-induced DNA Hypomethylation in early development. *Proceedings of the National Academy of Sciences of the United States of America*, 104, 13056–13061.
- Elias-Assad, G., Elias, M., Kanety, H., Pressman, A., & Tenenbaum-Rakover, Y. (2016). Persistent Mullerian duct syndrome caused by a novel mutation of an anti-Mullerian hormone receptor gene: Case presentation and literature review. *Pediatric Endocrinology Reviews*, 13, 731–740.
- Gearhart, J. P., & Jeffs, R. D. (1992). Exstrophy of the bladder, Epispadias, and other bladder anomalies. In P. C. Walsh, A. B. Retik, T. A. Stamey, & E. D. Vaughan, Jr. (Eds.) (6th ed), vol. 2. *Campbell's urology*. Philadelphia: W.B. Saunders Co.
- Gray, L. E., Jr., & Ostby, J. S. (1995). In utero 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (Tcdd) alters reproductive morphology and function in female rat offspring. *Toxicology and Applied Pharmacology*, 133, 285–294.
- Grishina, I. B., Kim, S. Y., Ferrara, C., Makarenkova, H. P., & Walden, P. D. (2005). Bmp7 inhibits branching morphogenesis in the prostate gland and interferes with notch signaling. *Developmental Biology*, 288, 334–347.

- Grote, D., Souabni, A., Busslinger, M., & Bouchard, M. (2006). Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. *Development*, *133*, 53–61.
- Guioli, S., Sekido, R., & Lovell-Badge, R. (2007). The origin of the Mullerian duct in Chick and Mouse. *Developmental Biology*, *302*, 389–398.
- Gupta, C. (2000). Reproductive malformation of the male offspring following maternal exposure to estrogenic chemicals. *Proceedings of the Society for Experimental Biology and Medicine*, *224*, 61–68.
- Harada, M., Omori, A., Nakahara, C., Nakagata, N., Akita, K., & Yamada, G. (2015). Tissue-specific roles of Fgf signaling in external genitalia development. *Developmental Dynamics*, *244*, 759–773.
- Haraguchi, R., Mo, R., Hui, C.-C., Motoyama, J., Makino, S., Shiroishi, T., Gaffield, W., & Yamada, G. (2001). Unique functions of sonic hedgehog signaling during external genitalia development. *Development*, *128*, 4241–4250.
- Keil, K. P., Ablter, L. L., Laporta, J., Altmann, H. M., Yang, B., Jarrard, D. F., Hernandez, L. L., & Vezina, C. M. (2014a). Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development. *Developmental Biology*, *396*, 237–245.
- Keil, K. P., Ablter, L. L., Mehta, V., Altmann, H. M., Laporta, J., Plisch, E. H., Suresh, M., Hernandez, L. L., & Vezina, C. M. (2014b). DNA methylation of E-cadherin is a priming mechanism for prostate development. *Developmental Biology*, *387*, 142–153.
- Keil, K. P., Altmann, H. M., Ablter, L. L., Hernandez, L. L., & Vezina, C. M. (2015). Histone acetylation regulates prostate ductal morphogenesis through a bone morphogenetic protein-dependent mechanism. *Developmental Dynamics*, *244*(11), 1404–1414.
- Kroovand, R. L., & Perlmutter, A. D. (1981). Congenital anomalies of the vas deferens and epididymis. In S. J. Kogan, & E. S. E. Hafez (Eds.), *Pediatric Andrology*. Dordrecht, Netherlands: Springer.
- Liu, L., Suzuki, K., Nakagata, N., Mihara, K., Matsumaru, D., Ogino, Y., Yashiro, K., Hamada, H., Liu, Z., Evans, S. M., Mendelsohn, C., & Yamada, G. (2012). Retinoic acid signaling regulates sonic hedgehog and bone morphogenetic protein Signalings during genital tubercle development. *Birth Defects Research. Part B, Developmental and Reproductive Toxicology*, *95*, 79–88.
- Mehta, V., Schmitz, C. T., Keil, K. P., Joshi, P. S., Ablter, L. L., Lin, T. M., Taketo, M. M., Sun, X., & Vezina, C. M. (2013). Beta-catenin (Ctnnb1) induces bmp expression in urogenital sinus epithelium and participates in prostatic bud initiation and patterning. *Developmental Biology*, *376*, 125–135.
- Miyagawa, S., Moon, A., Haraguchi, R., Inoue, C., Harada, M., Nakahara, C., Suzuki, K., Matsumaru, D., Kaneko, T., Matsuo, I., Yang, L., Taketo, M. M., Iguchi, T., Evans, S. M., & Yamada, G. (2009). Dosage-dependent hedgehog signals integrated with Wnt/B-catenin signaling regulate external genitalia formation as an appendicular program. *Development*, *136*, 3969–3978.
- Moore, K. L., & Persaud, T. V. N. (2003). *The developing human: Clinically oriented embryology* (7th ed.). Philadelphia: Elsevier.
- Orvis, G. D., & Behringer, R. R. (2007). Cellular mechanisms of Müllerian duct formation in the mouse. *Developmental Biology*, *306*, 493–504.
- Perriton, C. L., Powles, N., Chiang, C., Maconochie, M. K., & Cohn, M. J. (2002). Sonic hedgehog signaling from the urethral epithelium controls external genital development. *Developmental Biology*, *247*, 26–46.
- Peuckert, C., Aresh, B., Holenya, P., Adams, D., Sreedharan, S., Porthin, A., Andersson, L., Pettersson, H., Wolf, S., Klein, R., Oxburgh, L., & Kullander, K. (2016). Multimodal Eph/Ephrin signaling controls several phases of urogenital development. *Kidney International*, *90*, 373–388.
- Podlasek, C. A., Barnett, D. H., Clemens, J. Q., Bak, P. M., & Bushman, W. (1999). Prostate development requires sonic hedgehog expressed by the urogenital sinus epithelium. *Developmental Biology*, *209*, 28–39.
- Prusinski, L., Al-Hendy, A., & Yang, Q. (2016). Developmental exposure to endocrine disrupting chemicals alters the epigenome: Identification of reprogrammed targets. *Gynecology and Obstetrics Research: Open Journal*, *3*, 1–6.
- Rao, P. K., & Burnett, A. L. (2013). Development of the male reproductive system. In P. K. Kavoussi, R. A. Costabile, & A. Salonia (Eds.), *Clinical urologic endocrinology: Principles for Men's health*. London: Springer London.
- Ricke, W. A., Lee, C. W., Clapper, T. R., Schneider, A. J., Moore, R. W., Keil, K. P., Ablter, L. L., Wynder, J. L., Lopez Alvarado, A., Beaubrun, I., Vo, J., Bauman, T. M., Ricke, E. A., Peterson, R. E., & Vezina, C. M. (2016). In utero and Lactational Tcd exposure increases susceptibility to lower urinary tract dysfunction in adulthood. *Toxicol. Sci*, *150*(2), 429–440.
- Seifert, A. W., Harfe, B. D., & Cohn, M. J. (2008). Cell lineage analysis demonstrates an endodermal origin of the distal urethra and perineum. *Developmental Biology*, *318*, 143–152.
- Seifert, A. W., Bouldin, C. M., Choi, K. S., Harfe, B. D., & Cohn, M. J. (2009). Multiphasic and tissue-specific roles of sonic hedgehog in cloacal Septation and external genitalia development. *Development*, *136*, 3949–3957.
- Stuhrmann, M., & Dork, T. (2000). Cfr gene mutations and male infertility. *Andrologia*, *32*, 71–83.
- Suzuki, K., Matsumaru, D., Matsushita, S., Murashima, A., Ludwig, M., Reutter, H., & Yamada, G. (2017). Epispadias and the associated Embryopathies: Genetic and developmental basis. *Clinical Genetics*, *91*, 247–253.
- Thomson, A. A., & Cunha, G. R. (1999). Prostatic growth and development are regulated by Fgf10. *Development*, *126*, 3693–3701.
- Vezina, C. M., Allgeier, S. H., Fritz, W. A., Moore, R. W., Strerath, M., Bushman, W., & Peterson, R. E. (2008a). Retinoic acid induces prostatic bud formation. *Developmental Dynamics*, *237*, 1321–1333.
- Vezina, C. M., Allgeier, S. H., Moore, R. W., Lin, T. M., Bemis, J. C., Hardin, H. A., Gasiewicz, T. A., & Peterson, R. E. (2008b). Dioxin causes ventral prostate agenesis by disrupting Dorsorostral patterning in developing mouse prostate. *Toxicological Sciences*, *106*, 488–496.
- Weiss, A. C., Airik, R., Bohnenpoll, T., Greulich, F., Foik, A., Trowe, M. O., Rudat, C., Costantini, F., Adams, R. H., & Kispert, A. (2014). Nephric duct insertion requires EphA4/EphA7 signaling from the Pericloacal mesenchyme. *Development*, *141*, 3420–3430.
- Xu, K., Wu, X., Shapiro, E., Huang, H., Zhang, L., Hickling, D., Deng, Y., Lee, P., Li, J., Lepor, H., & Grishina, I. (2012). Bmp7 functions via a polarity mechanism to promote cloacal Septation. *PLoS One*, *7*, e29372.
- Yamada, G., Satoh, Y., Baskin, L. S., & Cunha, G. R. (2003). Cellular and molecular mechanisms of development of the external genitalia. *Differentiation*, *71*, 445–460.

### "Systems Biology of Reproduction"

Spring 2020 (Even Years) – Course Syllabus  
BIOL 475/575 Level Undergraduate/Graduate (3 Credit)  
SLN: (475) – 06061, (575) – 06062

Time - Tuesday and Thursday 10:35 am-11:50 am  
(Course Lectures on Blackboard/Panopto and Discussion Sessions on WSU Zoom for all campuses)

Room – CUE 418

Course Director – Michael Skinner, Abelson Hall 507, 335-1524, [skinner@wsu.edu](mailto:skinner@wsu.edu)

Co-Instructor – Eric Nilsson, Abelson Hall 507, 225-1835, [nilsson@wsu.edu](mailto:nilsson@wsu.edu)

#### Learning Objective -

Current literature based course on the Systems Biology of Reproduction. Learning Systems approaches to the biology of reproduction from a molecular to physiological level of understanding.

#### Schedule/Lecture Outline –

January 14 & 16	Week 1	Systems Biology Introduction
21 & 23	Week 2	Molecular/ Cellular/ Reproduction Systems
28 & 30	Week 3	Sex Determination Systems
February 4 & 6	Week 4	Male Reproductive Tract Development & Function
11 & 13	Week 5	Female Reproductive Tract Development & Function
18 & 20	Week 6	Gonadal Developmental Systems Biology
25 & 27	Week 7	Tesis Systems Biology
March 3 & 5	Week 8	Ovary Systems Biology
10 & 12	Week 9	Epigenetics and Transgenerational Gonadal Disease
16 – 20	Week 10	Spring Break
24 & 26	Week 11	Gametogenesis/ Stem Cells/ Cloning
31 & 2	Week 12	Hypothalamus-Pituitary Development & Function
April 7 & 9	Week 13	Reproductive Endocrinology Systems
14 & 16	Week 14	Fertilization & Implantation Systems
21 & 23	Week 15	Fetal Development & Birth Systems
28 & 30	Week 16	Assisted Reproduction/Contraception
May 5 & 7	Week 17	Exam or Grant Review

Spring 2020 – Systems Biology of Reproduction  
Lecture Outline – Male Reproductive Tract Development & Function  
Michael K. Skinner – Biol 475/575  
CUE 418, 10:35-11:50 am, Tuesday & Thursday  
February 4, 2020  
Week 4

#### Male Reproductive Tract Development & Function

##### Embryonic Development and Reproductive Tract Organogenesis

- Overview
- Development of Mullerian Duct vs. Duct Wolffian Duct Derivatives
- Mullerian Inhibiting Substance (MIS)

##### Male Urogenital Tract Organogenesis

- Prevention of Programmed Cell Death in the Wolffian Duct
- UGS/Prostate/Seminal Vesicle
  1. Prostate Morphogenesis (ductal branching)
  2. Cell-Cell Interactions and Paracrine Factors
  3. Prostate Cancer
- Epididymis/Ductus Deferens
- Role of Androgens (T versus DHT)
  1. Androgen Metabolism
  2.  $\alpha$  Reductase Inhibitors
  3. Organ Culture
- Endocrine Disruption

#### Required Reading

Moses MM and Behringer RR. (2019) Environ Epigenet. 25:5(3):dvz017.

Joseph and Vezina (2018) Male Reproductive Tract: Development Overview. in: Encyclopedia of Reproduction 2<sup>nd</sup> Ed. Vol. 1, Pages 248-255.

Spring 2018 – Systems Biology of Reproduction  
Discussion Outline – Male Reproductive Tract Development & Function  
Michael K. Skinner – Biol 475/575  
CUE 418, 10:35-11:50 am, Tuesday & Thursday  
February 1, 2018  
Week 4

#### Reproduction Tract Development & Function

##### Primary Papers:

1. Murashima, et al. (2015) Asian J Andrology 17:749-755
2. Okazawa, et al. (2015) Developmental Biology 400(1):139-47
3. Markert, et al. (2011) PNAS 108(52):21276-21281

##### Discussion

Student 7: Classic Reference 1 above

- What are the developmental steps of the Wolffian/epididymal duct?
- What are the Phenotypes of knockouts that explain the development?
- What technology was used





Student 8: Reference 2 above





- What is the technology used?
- Where is the expression pattern of the FGF receptor?
- What does the knockout phenotypes show on regional actions of FGF receptor?

Student 9: Reference 3 above

- What is the technology used?
- What did the expression patterns show?
- What basic information on prostate cancer was obtained?




# Development









**Region-specific regulation of cell proliferation by FGF receptor signaling during the Wolffian duct development.**

Okazawa M, et al.  
Dev Biol. 2015 Apr 1;400(1):139-47.



**Figure 3 | Müllerian duct regression.** The developing Müllerian ducts are visualized by *Lim1-lacZ* expression in the mouse embryo at embryonic day (E) 15. **a** | In XY male mice, Müllerian-inhibiting substance (MIS) is produced by the testes and eliminates the Müllerian ducts. The regressing Müllerian ducts (MD) have a fragmented pattern at this stage. **b** | When *Mis* is mutated by gene targeting in XY mice, there is no Müllerian duct regression. **c** | There is no Müllerian duct regression in the absence of MIS in XX female mice. **d** | When human *MIS* (*AMH*) is overexpressed using a metallothionein (*Mt*) promoter in XX mice, ectopic regression of the Müllerian duct is observed. A, anterior (cranial); K, kidney; L, left; *Lim*, *lin-11*, *Isl1* and *meis-3* transcription-factor homologue; OV, ovary; P, posterior (caudal); R, right; T, testis; WD, Wolffian duct. Panels **c** and **d** adapted from Ref. 11 © (2003) The Company of Biologists Ltd.





**Table 1. Effect of protease inhibitors on Müllerian duct regression**

Protease inhibitor	Target protease	% Regressed*	n†
Control analog	None	95	19
GM6001	Matrix metalloproteinases	5	22
Phosphoramidates	Matrix metalloproteinases	50	8
Equisin	Serine proteases	45	11
Aprotinin	Serine proteases	80	7
Leupeptin	Serine proteases	100	7
Boc-D-FMK	Caspases	0	9

\*Genital ridges with no Müllerian duct.  
†Total number of ridges tested. Experiments were repeated on 3-11 separate litters. Control analog and GM6001 were tested on male and female.  
\*MIS cultures; all other inhibitors were tested on males.

**Fig. 6. Potential roles of MMP2 in mediating Müllerian duct regression.** Activation of the MIS signaling cascade induces expression of MMP2 in the Müllerian duct mesenchyme. Latent or pro-MMP2 is secreted into the extracellular space, where it is activated to its mature form by membrane bound metalloproteinases such as MMP14. Cell death of the Müllerian duct epithelium may occur by MMP2 cleavage of a factor secreted by the mesenchyme. MMP2 activity may result in the degradation of a survival factor or activation of a death factor. Alternatively, MMP2 could cause apoptosis by cleaving substrates on the epithelial cell, such as the epithelial cell basement membrane.

Osterix functions downstream of anti-Müllerian hormone signaling to regulate Müllerian duct regression.  
 Mullen RD, Wang Y, Liu B, Moore EL, Behringer RR.  
 Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8382-8387.












FIG. 2. MIS: a cellular signal in the adult reproductive system. In the adult testis and ovary, MIS is expressed in Sertoli and granulosa cells, respectively. The MISIR is co-expressed with the MIS ligand in granulosa cells as well as the internal theca layer and in Leydig cells. Proposed functions for the MIS in the ovary have been implied from loss-of-function MIS or MISIR mouse mutants (Durlinger *et al.*, 1999). In the testis, MIS represses Leydig cell growth. For both gonads, MIS is implicated in repression of steroid production.




**Androgens and mammalian male reproductive tract development.**  
 Murashima A, Kishigami S, Thomson A, Yamada G.  
 Biochim Biophys Acta. 2015 Feb;1849(2):163-70.



A schematic diagram of male genital tract masculinization. WD epithelium is stabilized by androgen exposure, and the epididymis elongates and coils three-dimensional manner (left low and upper illustration). Prostate develops from the UGS. During sexual differentiation, solid buds from the urogenital sinus epithelium invade into the urogenital sinus mesenchyme where subsequent branching occurs (right low and upper illustration). Circulating or testis-derived androgens initiate these developmental processes through the mesenchymally expressed AR which regulates paracrine signaling to epithelia. Growth factor related genes which show tissue specific expression patterns are summarized in the scheme. \*lobe-specific expression.

**Reproductive tract biology: Of mice and men.**  
 Cunha GR, Sinclair A, Ricke WA, Robbey SJ, Cao M, Baskin LS.  
 Differentiation. 2019 Nov - Dec;110:49-63.



The mouse penile glans (A) lies within an extensive preputial space defined by the hair-bearing external prepuce, which forms the prominent elevation in the perineum. Comparison of (A & B) suggests homology between the human prepuce and the mouse "internal prepuce" (both red) in so far as both are integral to the distal aspect of the penis and encircle the glans. The MUMP (male urogenital mating protuberance) is a fibrocartilaginous process that extends ~1 mm beyond the urethral meatus in mice (A). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)





Diagram of divergent development of human penile urethral development. The distal portion of the human penile urethra (within the glans) develops via direct canalization of the urethral plate, while the proximal portion of the human penile urethra within the shaft forms via fusion of the urethral folds.

**Androgen Regulates Dimorphic F-Actin Assemblies in the Genital Organogenesis.**  
 Liu L, Suzuki K, Chun E, Murashima A, Sato Y, Nakagata N, Fujimori T, Yonemura S, He W, Yamada G.  
 Sex Dev. 2017;11(4):190-202.



# Prostate and Seminal Vesicle




Fig. 1. A, Adult human prostate in situ. Note the position of the prostate gland, the urethra immediately below the bladder and the location of the seminal vesicle and the urethra. B, Cross appearance of male urogenital system of the mouse (three-quarter view). The urethra have been cleared to facilitate the view. The prostate (VP) is located below the urethra and the seminal vesicle (SV) is located anteriorly in the space of the VP through the mesoderm. The urethra of the mouse (three-quarter view) are arranged along both sides of the urethra. BL, bladder; SV, seminal vesicle; UJ, urethra; VP, veraparin; LP, lateral prostate; DP, dorsal prostate. C, Three-dimensional model of the human prostate. Three-quarter frontal view. Upper portion shows epididymus. Central zone (red) and peripheral zone (yellow) of prostate are displayed in sagittal section. Lower portion shows associated prostatic epithelium (blue) and urethra. Anterior fibromuscular sheath (green) is not regularly to show right half only and is displaced to right (anteriorly) from urethra. Lower portion shows associated urethra as prostate apex and base (bladder neck). Transition zone contains central and peripheral zones only along distal urethral segment, which contains mesoderm. (From J. E. McNeal, *Anat. Rec.* 198, 1983, 131.)









Figure 1. Schematic diagram showing the structures of the male urogenital system (UGS) that develops into the adult human prostate and adult mouse prostate. (A) The adult human prostate is cross-shaped and composed of three zones: transitional zone, central zone, and peripheral zone. (B) In both the human and mouse prostate, the developing UGS epithelium buds out into the surrounding mesenchyme. (C) The mouse prostate has four prostates: lateral, dorsal, ventral, and anterior. (Panel A is based on data in McNeal 1983. Panel B is reprinted from Bhatia-Gaur et al. 1999, courtesy of Creative Commons License. Attribution-NonCommercial 4.0 International License. Panel C is reprinted from Cunha et al. 1987, adapted, with permission, from Oxford University Press © 2008.)



## Development of the human prostate.

Cunha GR, Vezina CM, Isaacson D, Ricke WA, Timms BG, Cao M, Franco O, Baskin LS. *Differentiation*. 2018 Sep - Oct;103:24-45.



UGS epithelium from a fetal mouse on gestation day 15 after removal of the mesenchyme. Images were taken by scanning electron microscopy (SEM) at successive 90° rotations of the sample, starting with a lateral view (A). Dotted line in (A) indicates that portion of the UGS from which prostatic buds will emerge. Arrowheads show where the Müllerian ducts entered the UGS epithelium. From Lin et al. (2003) with permission.








**Table 1** Proteins affecting branching morphogenesis in the prostate or seminal vesicles

Protein	Role in branching?	Supporting data for		Supporting evidence		References
		Prostate	Seminal vesicles	In vitro studies	Genetic studies	
AR	Promote	X	X	X	X	Takeda et al. (1986), Brown et al. (1988), Lubahn et al. (1989), Charest et al. (1991), Gaspar et al. (1991), He et al. (1991), Lamm et al. (2001)
BMP4	Inhibit	X		X	X	Grishina et al. (2005)
BMP7	Inhibit	X		X	X	Lamm et al. (2001)
FGF7	Promote	X	X	X	X	Alarid et al. (1994), Sugimura et al. (1996)
FGF10	Promote	X	X	X	X	Thomson and Cunha (1999), Donjacour et al. (2003)
FST	Promote	X		X	X	Canilla et al. (2001)
GDF7	Promote	X	X	X	X	Settle et al. (2001)
GHR	Promote	X		X	X	Ruan et al. (1999)
GLI2	Promote	X		X	X	Doles et al. (2006)
HOXA10	Promote	X	X	X	X	Podlask et al. (1999c)
HOXA13	Promote	X	X	X	X	Podlask et al. (1999b)
HOXB13	Promote	X		X	X	Economides and Capecchi (2003)
HOXD13	Promote	X	X	X	X	Podlask et al. (1997), Economides and Capecchi (2003)
IGF1	Promote	X		X	X	Ruan et al. (1999)
INHBA	Inhibit	X		X	X	Canilla et al. (2001)
NKX3.1	Promote	X		X	X	Bhatia-Gaur et al. (1999), Schneider et al. (2000), Tanaka et al. (2000)
p53	Promote	X		X	X	Signoretto et al. (2000)
SFRP1	Promote	X		X	X	Joesting et al. (2005)
TGFβ	Inhibit	X		X	X	Itoh et al. (1998), Tomlinson et al. (2004)
SHH	Context dependent regulator	X		X	X	Podlask et al. (1999a), Freestone et al. (2003), Wang et al. (2003), Lamm et al. (2002), Berman et al. (2004), Doles et al. (2006)
SMO	Context dependent regulator	X		X	X	Podlask et al. (1999a), Freestone et al. (2003), Wang et al. (2003), Lamm et al. (2002), Berman et al. (2004), Doles et al. (2006)
SRD5A2	Promote	X	X	X	X	Anderson et al. (1991), Mahendroo et al. (2001)

BMP, bone morphogenetic protein; FGF, fibroblast growth factor; TGF-β, transforming growth factor-β; SHH, sonic hedgehog.


Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer. Gonthier K, Poluri RTK, Audet-Walsh E. J Steroid Biochem Mol Biol. 2019 Jul;191:105367.





**TABLE 1** | Recent Advances in Paracrine Regulation of Prostate Development

Name	Process	Reference
Axin2	Expressed in budding and branching epithelium	18
Bmp2	Marker of the ventral prostate	16
Bmp7	Mesenchymal expression inhibits Notch and restricts budding	19
Lef1	Expressed in budding and branching epithelium	18
FGF10	Stromal expression promotes branching	20, 21
FGFR2	Epithelial expression is required for proper branching and optimal androgen responsiveness	20, 22
MMP2	Epithelial expression required for branching and reducing collagen deposition of stroma	23
Notch	Required for terminal differentiation of epithelium	24
SFRP1	Prostate initiation gene signature and branching	12, 13
Shh	Required for epithelial growth	25
SOX9	Promotes prostate budding (particularly VP and AP) and deletion reduces FGFR2 expression	26
Sulf1	Inhibits ductal branching and FGFR signaling	27
Wnt4	Prostate epithelium marker	18
Wnt7a	Prostate epithelium marker	18
Wnt9b	Prostate epithelium marker	18
Wnt10b	Marker for prostate buds and epithelium	16, 18



Histology of SVs and the prostate. The glandular structure of SVs and the prostate is visualized in standard paraffin-embedded tissue sections. The sections were stained with hematoxylin-eosin (HE) (A) and for basal cytokeratins 5/14 (B) as described in Jäämaa et al. (2010). The epithelium of both tissues consists of two major cell types, basal (B) and secretory (S) cells. Note the discontinuous layer of basal cells in SVs.




Figure 4. Tissue recombination experiments demonstrating the essential role of androgen receptor (AR) during prostate development. Prostate glands form that produce secretory products when wild-type (WT) mesonephral sinus (UGS) mesenchyme (UGM) and WT UGS epithelia (UGE) are combined and grafted in a male host animal. When Testicular feminization (*Tfm*), AR-mutant, embryonic UGM is combined with either WT UGE or *Tfm* UGE, no prostate structure forms and vagina-like differentiation occurs, demonstrating the essential role of mesenchymal AR in the early stages of prostate organogenesis acting in a paracrine fashion to promote epithelial bud growth. UGE from *Tfm* mutant embryos combined with WT UGM forms prostate structures with no secretory function. (From Cunha 2008; adapted, with permission, from Elsevier © 2008.)





Table 1 - Abundant EPS urine proteins identified following 2D gel separation.

Protein name*	Score	Peptide matches
AMBR/Alpha-1-microglobulin	1160	254
Gelsolin	1097	97
Intermediaphilin	1001	32
Basement membrane-specific N5 proteoglycan	981	60
Serum albumin	890	66
Ig kappa chain C regions	679	302
Inser-alpha-trypsin inhibitor heavy chain H4	657	45
Alpha-1B-glycoprotein	518	28
Prostate-specific antigen	478	21
Vesicular integral membrane protein, VIF36	477	12
Ig lambda chain C regions	455	41
Complement C3	432	9
Actin, cytoplasmic 1	391	18
Epithelial cadherin	352	7
Prostatic acid phosphatase	349	17
Protein S100-A9	312	11
CD4 adhesion molecule 4	294	5
Apolipoprotein D	290	9
Prostaglandin-H2 D-isomerase	227	5
Carboxypeptidase E	217	4
Zinc-alpha-2-glycoprotein	208	7
Tissueinhibitor of metalloproteinase	202	4
Cathepsin H	185	7
Alpha-1-antitrypsin	151	2
Methionine-rich glycoprotein	134	2
Annexin A5	133	5
Chromodulin precursor	124	5
14-3-3 protein epsilon	119	3
Proactivator polypeptide/Saposin-A	118	10
Monocyte differentiation antigen CD14	85	2
Endothelial protein C receptor	77	3
Metalloproteinase inhibitor 1	76	2
14-3-3 protein zeta/delta	75	3
Neural cell adhesion molecule 1	68	2



\*Gel spots were excised from 2D gels, then reduced, alkylated and digested with trypsin to release peptides. Mass spectrometric analysis was performed on an LTQ<sup>+</sup> Linear Ion Trap (ThermoFinnigan, San Jose, CA) mass spectrometer in the data-dependent acquisition mode. Survey full scan MS spectra (from m/z 300 to 1800) were acquired and the four most intense ions in a scan were sequentially isolated and fragmented in the linear ion trap (MS/MS). The peptide sequences were identified from their tandem mass spectra using Mascot, a probability based search engine (www.matrixscience.com) using the SwissProt database. The following search criteria were used: variable modifications: carbamidomethylation of cysteine and oxidation of methionine residues, 1 missed enzyme cleavage site and an error tolerance of 1.5 Da for MS and 0.8 Da for MS/MS.

## Prostate Cancer

**Prostate Luminal Progenitor Cells in Development and Cancer.**  
Zhang D, Zhao S, Li X, Kirk JS, Tang DG.  
Trends Cancer. 2018 Nov;4(11):769-783.




Hierarchy of Prostate Epithelial Cell Lineages. (A) A simplified cartoon illustrating the epithelial cell composition and glandular structure of the adult prostate. (B,C) Hierarchy of epithelial cell lineages during early prostate development (B) and homeostasis and regeneration (C), revealed by genetic lineage-tracing studies. Blue-curved arrows denote self-renewal and broken arrows indicate inconsistent results reported by different groups. Abbreviations: ECM, extracellular matrix; LP, luminal progenitor; SC, stem cell.





**Figure 1.** Differentially modified regions in circDNA in prostate cancer and control individuals. (A) Volcano plot of microarray data in prostate cancer and control samples using  $q$ -value as statistics. The  $x$ -axis represents DNA modification differences between groups, with coefficients expressed in the  $\log_2$  scale. Samples with increased microarray signals in prostate cancer and control individuals had positive and negative coefficients, respectively. The  $y$ -axis represents  $-\log_{10}$ -transformed  $q$ -values. The number of counts represented by each point in the plot is shown in a color gradient, from light gray to black (representing 1 and 400 probes, respectively). The horizontal red line depicts the cutoff value for the  $q$ -value ( $q = 0.05$ ). The vertical red line depicts the zero value, i.e. no differences in DNA modification. (B) Heatmap of the 181 loci with age- and disease-dependent DNA modification in our microarray data at  $q < 0.25$ . Samples are on the  $x$ -axis and PCA and Ctrl prefixes refer to prostate cancer and control samples, respectively. Differentially modified loci are placed on the  $y$ -axis. Biological groups are differentiated by colors on the upper bar: green for control samples and red for prostate cancer samples. Normalized array signals are represented on a gradient scale ranging from red (-7) to blue (7).

**A miRNA expression signature that separates between normal and malignant prostate tissues.**

Carlsson J, Davidsson S, et al. Cancer Cell Int. 2011 May 27;11(1):14.






**TABLE II. Genes Identified in the Genetic Prognostic Signature and the Hybrid Genetic and Clinical (Marked by \*) Predictive Model**

Gene symbol	Gene title	Mean expression in recurrent tumors	P-value	Occurrence frequencies
PAK3 <sup>*</sup>	P21 (CDKN1A)-activated kinase 3	Under-expressed	<9.0e-6	78 (79)
RPL23 <sup>*</sup>	Ribosomal protein L23	Over-expressed	<5.0e-5	79 (79)
EI24 <sup>*</sup>	Etoposide-induced 24 mRNA	Over-expressed	<3.0e-7	79 (79)
TGFB3 <sup>*</sup>	Transforming growth factor, beta 3	Under-expressed	<1.0e-5	79 (3)
RBM34 <sup>*</sup>	RNA-binding motif protein 34	Over-expressed	<3.0e-4	62 (8)
PCOLN3	Procollagen (type III) N-endopeptidase	Under-expressed	<3.0e-5	78
FUT7	Fucosyl transferase 7 (alpha (1,3) fucosyl transferase)	Under-expressed	<3.0e-3	30
RICS Rho	GTPase-activating protein	Over-expressed	<3.0e-6	8
MAP4K4	Mitogen-activated protein kinase 4	Over-expressed	<3.0e-5	5
CUTL1	Cut-like 1, CCAAT displacement protein ( <i>Drosophila</i> )	Over-expressed	<3.0e-5	2
ZNF324B	Zinc finger protein 324B	Under-expressed	<5.0e-4	1

The P-values, computed using a t-test, quantify the up- or down-regulation of a gene between patients with and without recurrence. The value inside and outside of the brackets in the last column is the number of iterative models in which a gene was selected in the hybrid and genetic models, respectively.



**Figure 1** A variety of endogenous and exogenous etiological factors contribute to epigenetic changes leading to heterogeneity of disease processes, which is implicated by the 'unique disease principle'. To simplify, only selected examples of those etiological factors are demonstrated. There are numerous interactions between the factors, which are not depicted for simplicity.

Cortese R, Kwan A, et al. (2012) Epigenetic markers of prostate cancer in plasma circulating DNA.  
*Hum Mol Genet.* 15;21(16):3619-31.

Table 1. Summary of pyrosequencing results.

Loci	Sample set 1 % Mod. Pca <sup>a</sup>	% Mod. Ctrl <sup>a</sup>	Disease p.val. <sup>b</sup>	Age p.val. <sup>b</sup>	Sample set 2 % Mod. Pca <sup>a</sup>	% Mod. Ctrl <sup>a</sup>	Disease p.val. <sup>b</sup>	Age p.val. <sup>b</sup>
<i>DLG2</i>	48.7 ± 22.0	45.6 ± 23.6	<b>0.02</b>	<b>0.02</b>	42.9 ± 14.7	41.9 ± 18.3	0.85	0.07
<i>GNG7</i>	38.4 ± 3.0	38.2 ± 2.4	0.74	0.40	37.9 ± 11.1	36.8 ± 7.8	0.93	0.21
<i>HPS2</i>	22.7 ± 13.7	16.1 ± 8.3	0.13	<b>0.02</b>	40.8 ± 20.0	29.8 ± 27.1	0.32	0.82
<i>KU41339</i>	38.8 ± 5.8	37.1 ± 10.9	$1 \times 10^{-3}$	$8 \times 10^{-4}$	30.8 ± 10.0	36.2 ± 6.4	$1 \times 10^{-4}$	0.05
<i>NUDC3</i>	59.4 ± 6.1	63.6 ± 9.0	0.09	0.19	67.6 ± 11.6	69.7 ± 11.1	0.47	0.76
<i>PCDH11</i>	66.6 ± 23.3	50.9 ± 36.2	0.51	0.69	58.4 ± 27.6	58.0 ± 25.0	0.97	0.77
<i>RNF219</i>	35.0 ± 18.1	55.0 ± 17.6	$3 \times 10^{-4}$	$3 \times 10^{-9}$	35.3 ± 31.8	46.2 ± 23.7	$1 \times 10^{-4}$	0.14

Statistically significant differences ( $p < 0.05$ ) are in bold.  
<sup>a</sup>Mean ctDNA modification per amplicon.  
<sup>b</sup>LME model p-values.









TABLE 2 | Drugs Targeting Prostate Development Pathways

Drug Name	Target	Phase of Development	Reference
Abiraterone	CYP17A1 inhibitor	Approved for castration-resistant prostate cancer, current trials with various drug combinations	58
ARN-509	AR antagonist	Phase I (NCT01171898) and Phase II (NCT01709734) trials in castration-resistant prostate cancer	57
Bicalutamide	AR antagonist	Approved for prostate cancer, current trials in combination with other drugs	62
Dutasteride	5 $\alpha$ reductase type II inhibitor	Approved BPH, current trials for combination therapy for BPH and prostate cancer	63
Enzalutamide	AR antagonist	Approved for castration-resistant prostate cancer, current trials in combination with abiraterone, leuprolide, and bicalutamide	64
Everolimus	PI3 kinase/mTOR inhibitor	Phase I (NCT01642732) and II (NCT01313559) clinical trials for advanced prostate cancer	59
Finasteride	5 $\alpha$ reductase type II inhibitor	Approved for BPH	63
Flutamide	AR antagonist	Approved for prostate cancer, current trials in combination therapies	62
Leuprolide	GnRH antagonist	Approved for prostate cancer, current trials in various combination therapies	62
Ridaforolimus	mTor inhibitor	Phase II prostate cancer trial (NCT00777959 and NCT00110188)	60
Vismodegib	Shh inhibitor	Phase III prostate cancer trial (NCT01163084) FDA approved for metastatic basal cell carcinoma	61

## Epididymis







**Sullivan R, Saez F. (2013) Epididymosomes, prostasomes, and liposomes: their roles in mammalian male reproductive physiology. *Reproduction*. 2013 Jun 14;146(1):R21-35.**

**Table 1** Proteins associated with epididymosomes<sup>a</sup>. Proteins from epididymosomes with known or proposed functions once transferred to spermatozoa during maturation.

Name	Abbreviation	Functions	Particularities	References
Macrophage migration inhibitory factor	MIF	Associated with sperm dense fibers: involved in motility	Chelation of Zn; disulfide-bound	Eickhoff et al. (2004, 2006) and Frenette et al. (2002, 2003, 2004, 2005, 2006, 2010)
Liprin α3	Pyfla3	Acrosome reaction	Estrogen-responsive element in the 5'UTR	Joshi et al. (2012)
Kinases cSrc	cSrc	Signaling cascade of capacitation	Essential in cauda epididymal development	Krapf et al. (2012)
Glutathione peroxidase 5	GPX5	Protection against oxidative stress (DNA integrity)	Seleno-independent GPX	Chabory et al. (2009)
Ubiquitin	UBC	Elimination of defective spermatozoa	Involved in proteasome activity	Fraille et al. (1996) and Satozky et al. (2001)
Epididymal sperm binding protein 5	CD52 (HE5)	Protection against immune response	Highly glycosylated GPI anchored to sperm surface	Kirchhoff & Hale (1996), for review
Epididymal sperm binding protein 1	ELSPBP1	Elimination of defective spermatozoa	Zn-dependent transfer from epididymosomes to spermatozoa	D'Amours et al. (2012a, 2012b)
P26b (hamster), P25b (bovine)	P26b/P25b	Sperm-zona pellucida interaction	GPI-anchored to sperm surface	Legare et al. (1999) and Frenette & Sullivan (2001)
Sperm adhesion molecule 1	SPAM1 (PH-20)	Different roles in fertilization	GPI-anchored to sperm surface	Martin-DeLeon (2006) and Griffiths et al. (2008)
Glioma pathogenesis-related protein 1	GLPRL1	Roles in fertilization	Belongs to the CAP family, GPI-anchored to sperm surface	Caballero et al. (2012) and Gibbs et al. (2010)
A disintegrin metalloproteases	ADAM2, ADAM3, ADAM7	Involved in fertilization	Behave as integral membrane proteins once transferred to sperm	Oh et al. (2005)
Methylmalonate-semialdehyde dehydrogenase	MMSDH	Unknown	Behave as peripheral and integral membrane protein once transferred to sperm	Suryawanshi et al. (2012)

<sup>a</sup>Proteomes of ram epididymosomes (exosomes-like), bovine caput, and cauda epididymosomes and of human epididymosomes collected from the proximal vas deferens during vasectomy procedures have been published by Gatti et al. (2005), Thimon et al. (2008a, 2008b) and Girouard et al. (2011) respectively.


Epididymosomes		Prostasomes	
Reference	Reference	Reference	Reference
Size: 25–300 nm	(1)	Size: 30–500 nm	(2)
Cellular origin: epididymal principal cells	(3)	Cellular origin: prostatic acinar cells	(2)
Extracellular release: Apocrine secretion	(3, 4)	Extracellular release: Exocytosis of storage vesicles	(5)
Function: Sperm maturation, transfer of proteins to the sperm surface	(6)	Function: Sperm motility, immunosuppressive, and antioxidant factor, and sperm capacitation	(7)
Lipids: cholesterol: phospholipid ratio = 0.5	(8, 9)	Lipids: cholesterol: phospholipid ratio = 2. High amount of sphingomyelin.	(10)

**Proteomic Profiling of Mouse Epididymosomes Reveals their Contributions to Post-testicular Sperm Maturation.**

Nixon B, De Iullis GN, Hart HM, et al. *Mol Cell Proteomics*. 2019 Mar 15;18(Suppl 1):S91-S108.

Table 1  
Summary of mouse epididymosome proteome data set

Total proteins identified	Au. peptide hits/peptide	Au. unique peptide hits/peptide	Au. protein coverage (%)	Number of differentially accumulated proteins (fold change > 1.5)			
				Caput vs. Caput	Caput vs. Caput	Caput vs. Caput	
Mouse epididymosomes	1640	15.1	11.8	29.0	168	344	474



**Table 1 Epididymal sperm proteins**

Sperm proteins modified or relocated during epididymal transit	Epididymal proteins that interact with spermatozoa
Spam1 <sup>1</sup>	CRISPI <sup>11</sup>
ADAM2 <sup>2</sup> , ADAM3 <sup>3</sup> , ADAM15 <sup>4</sup> , ADAM24 <sup>5</sup>	P26h <sup>12</sup>
α-mannosidase <sup>6</sup>	Clusterin <sup>13</sup>
CE9 <sup>7</sup>	HE1 <sup>14</sup> , HE2 <sup>15</sup> , HE4 <sup>16</sup> , HES <sup>17</sup> , HE12 <sup>18</sup>
β-galactosidase <sup>8</sup>	HEL7 <sup>19</sup>
Basigin <sup>9</sup>	SPAG1 <sup>20</sup>
α-enolase <sup>10</sup>	Eppin <sup>21</sup>
Grp78/Hsp70 <sup>10</sup>	Cystatin I <sup>22</sup>
Endoplasmic protein <sup>10</sup>	SED1 <sup>23</sup>
Phosphatidylethanolamine binding protein <sup>10</sup>	
Lactate dehydrogenase 3 <sup>10</sup>	
Testis lipid-binding protein <sup>10</sup>	
Cytokeratin <sup>10</sup>	
β-subunit F1-ATPase <sup>10</sup>	


<sup>1</sup>(Phelps et al., 1990); <sup>2</sup>(Lun and Blobel, 1997); <sup>3</sup>(Frayne et al., 1998); <sup>4</sup>(Pasten-Hidalgo et al., 2008); <sup>5</sup>(Zhu et al., 2001); <sup>6</sup>(Tubiani et al., 1995); <sup>7</sup>(Nehme et al., 1993); <sup>8</sup>(Scully et al., 1987); <sup>9</sup>(Saxena et al., 2002); <sup>10</sup>(Baker et al., 2005); <sup>11</sup>(Cohen et al., 2000); <sup>12</sup>(Legare et al., 1999); <sup>13</sup>(Sylvester et al., 1991); <sup>14</sup>(Kirchhoff et al., 1996); <sup>15</sup>(Osterhoff et al., 1994); <sup>16</sup>(Kirchhoff et al., 1991); <sup>17</sup>(Kirchhoff and Hale, 1996); <sup>18</sup>(Salmann et al., 2001); <sup>19</sup>(Lin et al., 2008); <sup>20</sup>(Yenugu et al., 2006); <sup>21</sup>(Richardson et al., 2001); <sup>22</sup>(Hamil et al., 2002); <sup>23</sup>(Enslin and Shur, 2003).

**Region-specific microRNA signatures in the human epididymis.**  
Browne JA, Leir SH, Eggen SE, Harris A. Asian J Androl. 2018 Nov-Dec;20(6):539-544.

**Table 1: Differentially expressed miRNAs comparing the caput, corpus and cauda epididymis cells**

miRNA	FPKM comparison	Log2 fold change	Actual fold change	Differential
<b>A.</b>				
miR-573	Caput	Corpus	4.68	25.7
miR-155	3.11	0.61	-2.36	5.1
miR-30c2	3.92	1.10	-1.83	3.6
<b>B.</b>				
miR-196a1	Caput	Cauda	5.10	34.4
miR-573	10.28	0.58	-4.15	17.8
miR-155	3.11	0.45	-2.77	6.8
miR-let7f	0.72	8.67	3.59	12.0
miR-770	2.12	24.47	3.53	11.5
miR-1204	8.54	89.13	3.38	10.4
<b>C.</b>				
miR-4730	Corpus	Cauda	infinitely	infinitely
miR-196a1	72.23	0.44	-7.37	165.2
miR-let7d	12.80	1.64	-2.97	7.8
miR-3916	34.98	9.98	-1.81	3.5
miR-1204	7.84	89.13	3.51	11.4
miR-675	0.42	2.90	2.79	6.9

A: caput vs corpus; B: caput vs cauda; C: corpus vs cauda. Cap: caput; Corp: corpus; Cau: cauda; FPKM: fragments per kilobase of transcript per million mapped reads.



Vas Deferens

### Mechanisms of adaptive supersensitivity in vas deferens.

Quintas LE, Noël F.  
Auton Neurosci. 2009 Mar 12;146(1-2):38-46.

Adaptive supersensitivity is a phenomenon characteristic of excitable tissues and discloses as a compensatory adjustment of tissue's response to unrelated stimulatory endogenous and exogenous substances after chronic interruption of excitatory neurotransmission. The mechanisms underlying such higher postjunctional sensitivity have been postulated for a variety of cell types. In smooth muscles, especially the vas deferens with its rich sympathetic innervation, the mechanisms responsible for supersensitivity are partly understood and appear to be different from one species to another. The present review provides a general understanding of adaptive supersensitivity and emphasizes early and recent information about the putative mechanisms involved in this phenomenon in rodent vas deferens.




Table 1  
Alteration of signaling proteins in supersensitive vas deferens

Protein	Species	Model	Technique	Change	Reference	
α1-adrenoceptor	Rat	Res	[ <sup>3</sup> H]WB4101 binding	+	Vitarabur et al., 1982	
			[ <sup>3</sup> H]PE-2254 binding	+	Abel et al., 1985	
	Den	Res	[ <sup>3</sup> H]PE-2254 binding	+	Nasseri et al., 1985	
			[ <sup>3</sup> H]WB4101 binding	↓	Hata et al., 1981	
	Guinea	Den	Res	[ <sup>3</sup> H]WB4101 binding	+	Hata et al., 1989
	PG	Den, Res	[ <sup>3</sup> H]WB4101 binding	+	Cowan et al., 1985	
α2-adrenoceptor	Rat	Den, Res, OHDA	[ <sup>3</sup> H]Kendrine binding	↑	Vitarabur et al., 1982	
			[ <sup>3</sup> H]Rauwolfidine binding	ND	Abel et al., 1985	
	Res	[ <sup>3</sup> H]Rauwolfidine binding	ND	Nasseri et al., 1985		
		[ <sup>3</sup> H]QNB binding	+	Hata et al., 1981		
Muscarinic receptor	Rat	Den	[ <sup>3</sup> H]QNB binding	+	Hata et al., 1981	
			[ <sup>3</sup> H]QNB binding	↑	Higuchi et al., 1985	
	Guinea	Den	[ <sup>3</sup> H]QNB binding	↑	Hata et al., 1989	
Na <sup>+</sup> /K <sup>+</sup> -ATPase α1 (or α1T) isoform	PG	Rat	Immunoblot	+	Quintas et al., 2000	
			Guinea	Res	Immunoblot	+
	Rat	Den	Immunoblot, [ <sup>3</sup> H] ouabain binding	↓	Quintas et al., 2000	
			Guinea	Den, Dec, PG	[ <sup>3</sup> H]ouabain binding	↓
	Res	OHDA	Immunoblot	↓	Heroldman et al., 1993	
			Res	Immunoblot	↓	Heroldman et al., 1995
SERCA 2	Rat	Den	Immunoblot	↓	Quintas et al., 2005	
PMCA	Rat	Den	Immunoblot	+	Quintas et al., 2005	
Ryanodine receptor	Rat	Den	[ <sup>3</sup> H]ryanodine binding	↓	Quintas et al., 2005	
			[ <sup>3</sup> H]thapsigargin binding	↓	Jurkiewicz et al., 1994	

Den = denervation; Dec = decentralization; Res = reserpine; Guan = guanethidine; OHDA = 6-hydroxydopamine; ND = not detected; WB4101 = 2-[2-(p-dimethoxy)-phenoxymethylamino]methylbenzimidazole; QNB = quinuclidinyl benzilate; PE = [2-[[4-hydroxyphenyl]ethylamino]methyl] tetrazone; SERCA = sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase; PMCA = plasma membrane Ca<sup>2+</sup>-ATPase.

## Endocrine

Role Testosterone -

- 1) Wolffian Duct Development
- 2) Male Reproduction Genitalia
- 3) External Genitalia




FIG. 7. Differentiation of the internal genitalia. (From ref. 256.)





FIG. 5. Enzymatic differentiation of the human fetal gonad. (Adapted from refs. 95 and 215.)




FIG. 6. Enzymatic differentiation of fetal rabbit ovaries and testes on day 18 of gestation.





Fig. 4. Onset of endocrine function in the fetal testis and ovary of the rabbit embryo. Each gonad begins to synthesize its characteristic hormone at approximately the same time, beginning on day 17.5 (Molitch et al. 1977)










Fig. 8. Mechanism by which androgens act to virilize the male embryo. T, testosterone; D, dihydrotestosterone; R, high affinity androgen receptor protein. Three types of mutations in this pathway have been particularly useful in proving the applicability of this model to the events in the male embryo, namely those that result in abnormalities in the 5α-reductase enzyme, disorders of the androgen receptor, and specific receptor positive resistance





**Regulatory roles of epithelial-mesenchymal interaction (EMI) during early and androgen dependent external genitalia development.**  
 Hyuga T, Suzuki K, Acebedo AR, Hashimoto D, Kajimoto M, Miyagawa S, Enmi JI, Yoshioka Y, Yamada G. *Differentiation*. 2019 Nov - Dec;110:29-35.

**Early and late (androgen dependent) processes for GT development**

	outgrowth	sexual differentiation
<b>Early-stage</b>	<b>Hedgehog</b> Haraguchi, <i>Development</i> , 2001 Pentton, <i>Dev Biol</i> , 2002  <b>Wnt, Fgf</b> Li, <i>Proc Natl Acad Sci</i> , 2013 Miyagawa, <i>Development</i> , 2009 Cell Death Differ, 2014  <b>Fgf</b> Haraguchi, <i>Development</i> , 2000 Pellet, <i>Development</i> , 2005 Ching, <i>Dev Biol</i> , 2014  <b>Bmp</b> Suzuki, <i>Development</i> , 2003 Kajioke, <i>Congenit Anom</i> , 2019	<b>Hedgehog</b> Miyagawa, <i>Endocrinology</i> , 2011 Chen Y, <i>Bio Reprod</i> , 2018 Zhang, <i>PLoS</i> , 2015  <b>Wnt, AP-1</b> Miyagawa, <i>Mol Endocrinol</i> , 2009 Matsushita, <i>Nat Rev Urol</i> , 2018 Tsujiki, <i>PLoS</i> , 2014  <b>AP-1; Akt3</b> Tannour-Louet, <i>Nat Med</i> , 2014 van der Zanden, <i>J Clin Endocrinol Metab</i> , 2010 Liu, <i>Horm Res</i> , 2005  <b>Non-muscle myosin II</b> Acebedo, <i>Commun Biol</i> , 2019
<b>Late-stage (androgen dependent)</b>		




**Endocrine Disruption and Disruptors**

Compounds that alter with hormone receptor and/or signal transduction to alter hormone actions.

Anti-androgenic chemicals that impact the androgen signaling pathway can affect male reproductive development via several different mechanisms of action resulting in slightly differing profiles of effects.

Compound	↓ Testosterone production				'Low dose' prominent malformations
	Binds AR	↓ Ins3	↓ mRNA	↓ activity w/no ↓ mRNA	
Vinclizolin	X	0	0	0	Retained nipples; Hypospadias; Agenesia of ventral prostate
Procymidone	X	0	0	0	Similar to Vinclozolin
Linuron	X	0	0	X	Epididymal and testis abnormalities; No gubernacular agenesia
Prochloraz	X	0	0	X	Similar to Vinclozolin
Diethyl phthalate	0	X	X	-	All three phthalates produce epididymal and testis abnormalities; Gubernacular agenesia
Diethylhexyl phthalate	0	X	X	-	

↓: decrease, X: a known mechanism, 0: does not act through this mechanism, ↓ activity w/no ↓ mRNA: an x here indicates enzyme activity is decreased but expression levels of mRNA for the enzyme are not affected.









TABLE 1. CLASSIFICATION OF DISORDERS OF SEX DEVELOPMENT

A. Non-endocrine DSD (malformative DSD)	B. Endocrine DSD
<i>A.I. Defective morphogenesis of the gonadal ducts</i>	<i>B.I. Dysgenetic DSD (abnormal gonadal differentiation)</i>
Müllerian duct aplasia	Complete or partial gonadal dysgenesis
Other uterine malformations	Asymmetric gonadal differentiation
Absence of the vasa deferentia	Ovotesticular DSD
<i>A.II. Defective morphogenesis of the cloaca and urogenital sinus</i>	<i>B.II. Non-dysgenetic DSD</i>
Cloacal malformations	Defective male hormone production or action in 46,XY
Exstrophy of the bladder	Defects of androgen production
Prostate defects	Androgen insensitivity (androgen receptor mutations)
<i>A.III. Defective morphogenesis of the primordia of the external genitalia</i>	Persistent Müllerian duct syndrome: defects of AMH production or AMH receptor mutations
Aphallia and micropenis	Excess of male hormones in 46,XX
Diphallia and bifid phallus	Congenital adrenal hyperplasias
<i>A.IV. Associated defects in the morphogenesis of the urogenital sinus and the primordia of the external genitalia</i>	Plaental aromatase defects
Isolated hypospadias	Adrenal or ovarian tumors
Epispadias	Idiogenic
Penoscrotal transposition	

TABLE 2. MALFORMATIVE (NONENDOCRINE) DISORDERS OF SEX DEVELOPMENT IN WHICH A GENETIC ETIOLOGY HAS BEEN IDENTIFIED

Syndrome	Gene mutation	Defect	OMIM*
Mayer-Rokitansky-Küster-Hauser	WNT4, LHX1, TBX6	Müllerian derivative malformation or agenesis	277000
MURCS association		Müllerian derivative malformation or agenesis, unilateral renal agenesis, and cervico-thoracic somite dysplasia	601076
RCAD (renal cysts and diabetes)	HNF1B	Müllerian aplasia and renal dysfunction	137920
McKusick-Kaufman	MKKS	Vaginal atresia	236700
Hand-foot-genital	HOXA13	Hypospadias; vagina, uterus, and bladder malformations	140000
Velocardiofacial	Del 22q11.2, TBX1	Hypospadias; Müllerian aplasia and renal dysfunction	192430
Cystic fibrosis	CFTR	Congenital absence of vasa deferentia	277180
Robinow	WNT5A	Aphallia or micropenis	180700
Opitz G/BBB	MID1	Hypospadias	300000
Bladder exstrophy and epispadias complex	PERP	Epispadias associated to bladder exstrophy	600057

\*OMIM: Online Mendelian Inheritance of Man (available at: <http://www.ncbi.nlm.nih.gov/omim>).






Figure 23-5. Diagrammatic summary of normal sex determination, differentiation, and development in humans. MIS, müllerian inhibiting substance; T, testosterone or other androgen.



Y CHROMOSOME  
SRY  
AUTOSOME  
- WT1 (WILM'S TUMOR SUPPRESSOR)  
- Sox9  
X CHROMOSOME  
055

FIG. 1. A. Formation of the urogenital ridge in the embryo. The development of the intermediate mesoderm into the urogenital ridge during the embryonic period sets the stage for later differentiation into the gonads, Wolffian and Müllerian ducts. Under the control of several sex-independent genes, the ridge takes shape awaiting the sex-dependent signals that will evoke gonadal identity and the subsequent reproductive duct growth. B. Gonadogenesis and reproductive duct development. Later in embryonic development at least six gonad-determining genes (SF-1, Lim 1, WT-1, GATA-4, Lhx 9, and Emx2) direct formation of the indifferent gonads from the intermediate mesoderm. Absence of any of these genes blocks gonadal development. Thereafter, in males the genes necessary for normal testes, Sry, SF-1, Sox-9, and Ddx1 act to produce the gonad. The secretion of testosterone and MIS ensure the development of the normal male phenotype. In females, on the other hand, the lack of male determining genes allows for the development of ovaries. Wnt-4, Fc, and several of the Hoxa genes promote the proper growth and development of the Fallopian tubes, uterus, cervix, and vagina.



### Schedule/Lecture Outline –

January	14 & 16	Week 1	Systems Biology Introduction
	21 & 23	Week 2	Molecular/ Cellular/ Reproduction Systems
	28 & 30	Week 3	Sex Determination Systems
February	4 & 6	Week 4	Male Reproductive Tract Development & Function
	11 & 13	Week 5	Female Reproductive Tract Development & Function
	18 & 20	Week 6	Gonadal Developmental Systems Biology
	25 & 27	Week 7	Testis Systems Biology
March	3 & 5	Week 8	Ovary Systems Biology
	10 & 12	Week 9	Epigenetics and Transgenerational Gonadal Disease
	<b>16 – 20</b>	<b>Week 10</b>	<b>Spring Break</b>
	24 & 26	Week 11	Gametogenesis/ Stem Cells/ Cloning
	31 & 2	Week 12	Hypothalamus-Pituitary Development & Function
April	7 & 9	Week 13	Reproductive Endocrinology Systems
	14 & 16	Week 14	Fertilization & Implantation Systems
	21 & 23	Week 15	Fetal Development & Birth Systems
	28 & 30	Week 16	Assisted Reproduction/Contraception
May	5 & 7	Week 17	Exam or Grant Review